Adult ADHD: Less hyperactivity, but lingering inattention and distress

Article Type
Changed
Tue, 12/11/2018 - 15:12
Display Headline
Adult ADHD: Less hyperactivity, but lingering inattention and distress

Attention-deficit/hyperactivity disorder (ADHD) may be the only mental disorder that was discovered in children and later acknowledged in adults. Although controlled studies of adults with ADHD are few, we know that ADHD is common in adults, it can be diagnosed reliably, and 75% of those treated respond to treatment.1

The hallmark symptom of ADHD in children—hyperactivity—is usually attenuated in adults. In fact, some adults prefer the term ADD to ADHD because they are not hyperactive. This may be especially true of women, as their attention problems during childhood often were not recognized as ADHD (Box 1).

Box 1

WHY ADHD IS OFTEN MISSED IN GIRLS

In childhood, girls with ADHD typically present with attention problems and over-talkativeness, rather than hyperactivity. Talking too much does not disrupt the classroom as much as the larger-scale misbehavior of boys with ADHD, so the diagnosis is often missed in these girls. Overtalkativeness was added to the DSM-III-R criteria for ADHD in 1987, after it was recognized as a symptom of overactivity.

Now in midlife, many women with undiagnosed ADHD have children with ADHD. As they bring their children to treatment, these women are recognizing similar attention deficit symptoms from their own childhoods and are getting the help they need. As adults, many have low self-esteem, low energy, and weight problems. Among adults with ADHD, these women may be the most underdiagnosed.

Characteristics of adult ADHD

Adults with ADHD visit a psychiatrist for a variety of reasons. Often they are parents of children diagnosed with ADHD, and the possibility that they are similarly affected has arisen during their children’s evaluation and treatment. Sometimes they have recognized themselves in consumer articles about ADHD, or others have seen them in this light.

Adults with ADHD continue to experience their childhood difficulties in sustaining attention, listening, following instructions, and organizing tasks; inattention to details; lack of sustained mental effort; losing things; distractibility, and forgetfulness. Typical complaints include underachievement and poor adjustment at work or home. Comorbid ADHD may also be identified in patients who present with depression, anxiety, substance misuse, and mood swings.

The cognitive impairment of ADHD continues into adulthood, even in adults without hyperactive symptoms. It may be that adults are not hyperactive because the basal ganglia, which control motor activity in the brain, have over the years accommodated the problem through behavior modification or neurodevelopmental changes in late adolescence.2

Children with ADHD have abnormal cerebrospinal fluid (CSF) and blood levels of the dopaminergic metabolite homovanillic acid (HVA), but adults with ADHD may not. The primary origin for CSF HVA is the nigrostriatum, which suggests that subcortical dopaminergic nuclei are more often affected in children than adults.2 This may mean that compensatory changes occur as persons with ADHD mature, or perhaps the forms of ADHD that persist into adulthood have a different pathology or pathophysiology.

Comorbidities with ADHD

Rarely does one see pure ADHD; comorbidity is the rule. ADHD can be diagnosed quickly if you know what to look for. But a facile diagnosis may overlook a comorbidity that must be treated first—especially if you plan to use stimulants. Many patients with ADHD also have bipolar disorder, and a smaller proportion of patients with bipolar disorder have undetected ADHD. Placing a patient with undetected bipolar disorder on a stimulant could precipitate mania.

Table 1

COMMON COMORBIDITIES WITH ADHD

Bipolar disorder
Anxiety disorder
Depression
Drug dependence
Personality disorders
Somatoform disorders
Tourette’s disorder
Obsessive-compulsive disorder
Intermittent explosive disorder
Impulse control problems
 Addictive behaviors
 Sexual problems
 Compulsive gambling
Learning disabilities
Asperger’s syndrome

From the initial assessment, your treatment plan must address comorbid conditions (Table 1). This means taking a good history that includes corroborating information from relatives and data from the past, if possible. The case will then be much easier to manage, and quality of care greatly enhanced.

Stimulants: Usual first-choice therapy

In most cases, adult ADHD responds well to stimulant medications, although most available evidence is limited to studies in children. Several nonstimulant medications are also available, and the FDA is considering a new-drug application for a medication indicated for adult ADHD. Stimulants produce significant improvement in 30% of patients and mixed results in another 40%. Comorbidities may account for the 10 to 30% of patients who do not respond to stimulant therapy.

Methylphenidate, taken multiple times daily, is the most common treatment for ADHD. Dextroamphetamine and mixed salts of amphetamine also are used (Table 2).3 Patients usually respond to either methylphenidate or an amphetamine, and typically 25% of those who do not respond to one will respond to the other. When the clinical efficacy of amphetamines diminishes over time, many psychiatrists rotate medications. Replacing one amphetamine with another often eliminates the need to slowly increase the dosage and allows the clinician to maintain a relatively stable regimen.

 

 

When administering stimulants to adults, consider the individual’s total dosage requirement and daily schedule. Will he or she fare better with multiple daily dosing or a sustained-release form? How long is his or her average day? Does the patient have to be alert for 12 hours—or longer?

Some patients cannot sleep unless they take their last stimulant dose at bedtime. Others will have insomnia if a last dose is taken too late in the afternoon, especially with a sustained-release formulation.

When starting a patient on stimulants, begin with a 12-hour day and titrate the dosage—usually up, sometimes down—depending on response and side effects. Educating patients about their medications enables them to participate in decision-making.

Common side effects of stimulants include insomnia, decreased appetite, upset stomach, headache, anxiety, agitation, and increased pulse rate and blood pressure. The increase in blood pressure is usually less than 10%, but patients with poorly controlled hypertension should not be treated with stimulants until their blood pressure is well controlled. Until more is known about long-term effects, periodic assessment of blood pressure may be warranted.

Table 2

STIMULANT THERAPY FOR ADULTS WITH ADHD

StimulantsStarting dosageTitration rateUsual dosing intervalMaximum dosage in adults
Methylphenidate
Short-acting
d, l-methylphenidate (Ritalin, Methylin)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 3 to 4 hours Usually bid-tidAverage oral dosage 0.92 mg/kg/d; best response to 1.0 mg/kg/d16
Intermediate-acting
d, l-methylphenidate (Ritalin SR, Metadate ER, Methylin ER)20 mg Ritalin SR; 10 mg Methylin ER or Metadate ER10 to 20 mg per weekqd to bid 
d-methylphenidate (Focalin)2.5 mg bid2.5 to 5 mg per weekbid, at least 4 hours apart 
Long-acting
d, l-methylphenidate (Concerta)18 mg qd18 mg every 3 to 5 days12+ hours, usually qd 
d, l-methylphenidate (Metadate CD)20 mg qd20 mg per weekqd 
Amphetamine
Short-acting
(Dexedrine, Dextrostat)2.5 to 5 mg qd2.5 to 5 mg every 3 to 5 daysEvery 4 to 6 hours Usually bid-tid 
Intermediate-acting
Mixed salts (Adderall)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 4 to 6 hours Usually qd to bidAverage dosage 54 mg/d divided in two doses; maximum 30 mg bid
(Dexedrine Spansule)5 or 10 mg qd5 mg per weekqd 
Long-acting
(Adderall XR)10 mg qd10 mg per weekqd 
Stimulant
Pemoline (Cylert)37.5 mg qd18.75 mg per weekqd; typical range 56.25 to 75 mg qdMaximum dosage 112.5 mg/d

Box 2

NONDRUG THERAPIES FOR ADULTS WITH ADHD

  • Organized and orderly home and working environment
  • Designated work/study space at home
  • Designated coach to supervise work/study
  • Healthy meals at regularly scheduled times
  • Regular exercise

Adults with ADHD have been treated with mixed amphetamine salts with positive results. In a 7-week controlled, crossover study, 27 adults with ADHD received an average of 54 mg/d administered in two doses. Symptoms improved significantly—a 42% decrease on the ADHD Rating Scale. The medication was well-tolerated, and 70% of those receiving mixed amphetamine salts improved, compared with 7% of those who received a placebo.4

Duration of action of mixed salts of amphetamine has been measured at 3.5 hours with a 5-mg dose and 6.4 hours with a 20-mg dose.5 With methylphenidate, a dose of 12.5 mg worked for 4 hours. The maximum recommended dosage of mixed salts of amphetamine is 40 mg/d in divided doses.

Stimulant medications are well-tolerated. Addiction and the need for increased dosages can occur over long-term use (months to years). Reducing the dosage or switching from methylphenidate to an amphetamine variant can usually prevent these problems.

The FDA recently approved a single-enantiomer form of methylphenidate. It contains only the active “d” enantiomer, whereas the racemic mixture contains both the “d” and “l” enantiomers. Because the “l” enantiomer is inert, the resulting medication is more potent and may be prescribed at half the dosage of the racemic mixture.

Pemoline, a once-daily stimulant, is considered a second-line treatment because of reports of hepatic failure in some patients. Its use requires written informed consent and liver function tests at baseline and every 2 weeks. In a controlled trial, pemoline at high dosages (120 to 160 mg/d) was found moderately effective in adults with ADHD.6

Newer options: Longer-acting stimulants

Newer forms of slow-release methylphenidate and mixed amphetamine salts with sophisticated delivery systems are available.

Metadate CD is delivered in capsules containing beads with polymer coatings that dissolve and release their contents at different times. The capsules contain a 30:70 ratio of immediate- and extended-release beads.

Metadate CD has not been tested for adults in controlled clinical trials. In children ages 6 to 15, a single morning dose has been shown to be clinically effective in the morning and afternoon. A supplemental immediate-release capsule can be given in the morning if a patient’s medication levels need to be increased quickly. Dosage supplementation may also be required later in the day.

 

 

Concerta is delivered in 18-mg and 36-mg tablets. The immediate-release coating on the tablets delivers medication within the first hour. The drug inside then dissolves in the GI tract and is released at a controlled rate by osmotic pressure. The indigestible tablet is passed in the stool.

Concerta was investigated in children ages 6 to 12 and provides 10 to 12 hours of sustained medication. From child studies, we know that when a patient takes a 36-mg tablet at 6 AM, blood levels decline in late afternoon. An 18-mg dose at noon covers the 4 to 6 hours needed for evening chores.

Adderall XR is an extended-release, once-daily form of mixed amphetamine salts. No controlled trials of this formulation are available in adults with ADHD. Its efficacy was established after two clinical trials of children aged 6 to 12 who met DSM-IV criteria for ADHD.

Individualized and flexible dosing improves symptom control and compliance when treating adults with ADHD. For some patients, once-daily dosing is more convenient than multiple doses, while others prefer the immediate-release form because they like its midday “pause” and bid dosing. The immediate-release tablet allows the flexibility of bid or tid dosing, depending on the day’s requirements.

Antidepressants: Another choice

Antidepressants are usually considered second-line treatment for ADHD because of concerns about efficacy and side effects. The few available studies show antidepressants work as well as stimulants but more slowly. It is good practice, therefore, to advise patients that—unlike feeling the effect of a stimulant in 60 minutes—they will not feel an effect from an antidepressant for days or weeks, and that achieving an optimal effect may take 4 to 6 weeks.

Antidepressants have several advantages over stimulants. They are not classified as narcotics, work without the on-off effects of stimulants, and can treat comorbid depression and anxiety. For adult ADHD, the most effective agents work on the catecholamine systems—norepinephrine and/or dopamine. This includes the tricyclic antidepressants, MAO inhibitors, bupropion, and venlafaxine. The serotonin reuptake inhibitors have not shown promise in ADHD, nor have mirtazapine or nefazodone demonstrated much effect.

Desipramine, a tricyclic antidepressant, is a strong inhibitor of norepinephrine reuptake. In a double-blind, controlled study in 41 adults with ADHD, 68% of patients receiving desipramine, 200 mg/d, responded positively, compared with no patients who took a placebo.7

When venlafaxine was given in standard dosages to 10 adults with ADHD in an open, 8-week clinical trial, an effect was seen by week two. Of the nine patients who completed the study, seven were considered responders. Symptoms were reduced significantly with venlafaxine treatment, and most side effects were mild.8

In an open study, bupropion treatment resulted in moderate to marked response in 74% of 19 patients. Ten of those patients who responded chose to continue bupropion rather than their previous medication.9 In a 6-week controlled study of 40 patients, bupropion use was associated with a 42% reduction in ADHD symptoms in the 38 patients who completed the study. Patients who received a placebo showed only a 24% reduction in symptoms. According to the CGI, 52% of patients who received bupropion reported being “much improved” or “very improved” compared with 11% of those receiving a placebo.10

Other treatment options that have shown mixed results include modafinil, alpha-2a agonists, acetylcholinesterase inhibitors, and the histaminergic agents.

Managing adverse effects

Substance abuse Stimulant abuse has been a concern, but it has not become the problem many feared. In fact, some studies have found that methylphenidate may help stanch the craving for cocaine in adults with ADHD.11,12 Treating ADHD with pharmacotherapy also has been shown to reduce the risk for substance abuse in adolescence by 85%.13

With careful screening, you can usually identify drug-seeking behavior in adult patients. For patients with substance abuse problems, you can prescribe the nonstimulants.

Tics that can occur with stimulant medications usually can be suppressed by reducing the dosage, being vigilant, and waiting it out. Tics may ameliorate over weeks to months.

Cardiac and cognitive effects Long-term use of stimulant medications at high dosages has been associated with cardiac and cognitive toxicity, as noted in the 1998 NIH consensus statement on diagnosis and treatment of ADHD. It is important to provide patients with this information as part of their informed-consent briefing. (See “Related resources,” to view the consensus statement.)

Nonpharmacologic management

Nonpharmacologic treatments such as EEG biofeedback; psychoeducational approaches; and individual, family, and group psychotherapy are widely used to treat adults with ADHD. Clinicians and patients often perceive these interventions as beneficial, although none have been tested in randomized, placebo-controlled studies.

 

 

Patients often function better when their home and work environments are thoughtfully organized, with a designated work/study space and regularly scheduled times for meals, sleep, and exercise. An ADHD coach may facilitate such structure and discipline (Box 2).

New agents in the pipeline

Efforts are being made to increase awareness of adult ADHD and to improve its treatment. For example, the National Institute of Mental Health is funding research on adult ADHD and displays on its Web site a PET scan of an adult brain with ADHD (see “Related resources”).14 Several medications also are being developed to treat ADHD.

Atomoxetine, a nonstimulant medication awaiting FDA approval for adult ADHD, is a selective norepinephrine reuptake inhibitor. In a double-blind, placebo-controlled, crossover study of adults with well-characterized ADHD, 11 of 21 patients improved with use of atomoxetine, compared with 2 of 21 who improved with use of a placebo. The average dosage of 76 mg/d was well-tolerated.15 The 52% response rate is similar to the 54% average improvement rate reported for methylphenidate in previous studies of adult ADHD.

In clinical trials, atomoxetine was given bid. Insomnia was not a side effect, so bid dosing does not interfere with sleep. Approximately 10 to 15% of patients experienced weight loss as a side effect.

Other treatment options under development include:

  • a transdermal system for delivery of methylphenidate16
  • a novel nicotinic analogue
  • glutamate AMPA receptor modulation
  • omega-3 fatty acids.

Related resources

  • Hallowell EM, Ratey JJ. Driven to distraction: Recognizing and coping with attention deficit disorder from childhood through adulthood. New York: Simon and Schuster; Reprint edition 1995.
  • Solanto MV, Arnstein AFT, Castellanos FX, eds. Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press; 2001.
  • Weiss M, Trokenberg-Hechtman L, Weiss G. ADHD in adulthood: A guide to current theory, diagnosis, and treatment. Baltimore: Johns Hopkins University Press; 1999.
  • National Institute of Mental Health. http://www.nimh.nih.gov

Drug brand names

  • Atomoxetine • (investigational)
  • Bupropion • Wellbutrin
  • Desipramine • Norpramin
  • Dextroamphetamine • Dexedrine, Dextrostat
  • Methamphetamine • Desoxyn
  • Methylphenidate • Focalin, Ritalin
  • Methylphenidate SR • Concerta, Metadate CD, Metadate ER, Methylin ER, Ritalin SR
  • Mixed salts of amphetamine • Adderall, Adderall XR
  • Modafinil • Provigil
  • Pemoline • Cylert
  • Venlafaxine • Effexor

Disclosure

The author reports that he serves as a consultant to Eli Lilly and Company and is on the speaker’s bureaus of Wyeth Pharmaceuticals and AstraZeneca.

References

1. Gadrow KD, Weiss M. Attention-deficit/hyperactivity disorder in adults: beyond controversy. Arch Gen Psychiatry 2001;58(8):784-5.

2. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998;18(15):5901-7.

3. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43.

4. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58(8):775-82.

5. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34(1):55-60.

6. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19(3):257-64.

7. Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995;183(1):48-50.

8. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57(5):184-9.

9. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147(8):1018-20.

10. Wilens TE, Spencer TJ, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158(2):282-8.

11. Grabowski J, Roache JD, Schmitz JM, Rhoades H, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17(6):485-8.

12. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59(6):300-5.

13. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104(2):e20.-

14. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 1990;323(20):1361-6.

15. Spencer T, Biederman J, Wilens T. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155(5):693-5.

16. Noven Pharmaceuticals. The Science of Noven. Research and development. Transdermal technology. Available at: http://www.noven.com/research.htm.

Author and Disclosure Information

Michael Alan Schwartz, MD
Clinical professor, department of psychiatry Case Western Reserve University School of Medicine Cleveland, OH

Issue
Current Psychiatry - 01(10)
Publications
Topics
Page Number
34-43
Sections
Author and Disclosure Information

Michael Alan Schwartz, MD
Clinical professor, department of psychiatry Case Western Reserve University School of Medicine Cleveland, OH

Author and Disclosure Information

Michael Alan Schwartz, MD
Clinical professor, department of psychiatry Case Western Reserve University School of Medicine Cleveland, OH

Attention-deficit/hyperactivity disorder (ADHD) may be the only mental disorder that was discovered in children and later acknowledged in adults. Although controlled studies of adults with ADHD are few, we know that ADHD is common in adults, it can be diagnosed reliably, and 75% of those treated respond to treatment.1

The hallmark symptom of ADHD in children—hyperactivity—is usually attenuated in adults. In fact, some adults prefer the term ADD to ADHD because they are not hyperactive. This may be especially true of women, as their attention problems during childhood often were not recognized as ADHD (Box 1).

Box 1

WHY ADHD IS OFTEN MISSED IN GIRLS

In childhood, girls with ADHD typically present with attention problems and over-talkativeness, rather than hyperactivity. Talking too much does not disrupt the classroom as much as the larger-scale misbehavior of boys with ADHD, so the diagnosis is often missed in these girls. Overtalkativeness was added to the DSM-III-R criteria for ADHD in 1987, after it was recognized as a symptom of overactivity.

Now in midlife, many women with undiagnosed ADHD have children with ADHD. As they bring their children to treatment, these women are recognizing similar attention deficit symptoms from their own childhoods and are getting the help they need. As adults, many have low self-esteem, low energy, and weight problems. Among adults with ADHD, these women may be the most underdiagnosed.

Characteristics of adult ADHD

Adults with ADHD visit a psychiatrist for a variety of reasons. Often they are parents of children diagnosed with ADHD, and the possibility that they are similarly affected has arisen during their children’s evaluation and treatment. Sometimes they have recognized themselves in consumer articles about ADHD, or others have seen them in this light.

Adults with ADHD continue to experience their childhood difficulties in sustaining attention, listening, following instructions, and organizing tasks; inattention to details; lack of sustained mental effort; losing things; distractibility, and forgetfulness. Typical complaints include underachievement and poor adjustment at work or home. Comorbid ADHD may also be identified in patients who present with depression, anxiety, substance misuse, and mood swings.

The cognitive impairment of ADHD continues into adulthood, even in adults without hyperactive symptoms. It may be that adults are not hyperactive because the basal ganglia, which control motor activity in the brain, have over the years accommodated the problem through behavior modification or neurodevelopmental changes in late adolescence.2

Children with ADHD have abnormal cerebrospinal fluid (CSF) and blood levels of the dopaminergic metabolite homovanillic acid (HVA), but adults with ADHD may not. The primary origin for CSF HVA is the nigrostriatum, which suggests that subcortical dopaminergic nuclei are more often affected in children than adults.2 This may mean that compensatory changes occur as persons with ADHD mature, or perhaps the forms of ADHD that persist into adulthood have a different pathology or pathophysiology.

Comorbidities with ADHD

Rarely does one see pure ADHD; comorbidity is the rule. ADHD can be diagnosed quickly if you know what to look for. But a facile diagnosis may overlook a comorbidity that must be treated first—especially if you plan to use stimulants. Many patients with ADHD also have bipolar disorder, and a smaller proportion of patients with bipolar disorder have undetected ADHD. Placing a patient with undetected bipolar disorder on a stimulant could precipitate mania.

Table 1

COMMON COMORBIDITIES WITH ADHD

Bipolar disorder
Anxiety disorder
Depression
Drug dependence
Personality disorders
Somatoform disorders
Tourette’s disorder
Obsessive-compulsive disorder
Intermittent explosive disorder
Impulse control problems
 Addictive behaviors
 Sexual problems
 Compulsive gambling
Learning disabilities
Asperger’s syndrome

From the initial assessment, your treatment plan must address comorbid conditions (Table 1). This means taking a good history that includes corroborating information from relatives and data from the past, if possible. The case will then be much easier to manage, and quality of care greatly enhanced.

Stimulants: Usual first-choice therapy

In most cases, adult ADHD responds well to stimulant medications, although most available evidence is limited to studies in children. Several nonstimulant medications are also available, and the FDA is considering a new-drug application for a medication indicated for adult ADHD. Stimulants produce significant improvement in 30% of patients and mixed results in another 40%. Comorbidities may account for the 10 to 30% of patients who do not respond to stimulant therapy.

Methylphenidate, taken multiple times daily, is the most common treatment for ADHD. Dextroamphetamine and mixed salts of amphetamine also are used (Table 2).3 Patients usually respond to either methylphenidate or an amphetamine, and typically 25% of those who do not respond to one will respond to the other. When the clinical efficacy of amphetamines diminishes over time, many psychiatrists rotate medications. Replacing one amphetamine with another often eliminates the need to slowly increase the dosage and allows the clinician to maintain a relatively stable regimen.

 

 

When administering stimulants to adults, consider the individual’s total dosage requirement and daily schedule. Will he or she fare better with multiple daily dosing or a sustained-release form? How long is his or her average day? Does the patient have to be alert for 12 hours—or longer?

Some patients cannot sleep unless they take their last stimulant dose at bedtime. Others will have insomnia if a last dose is taken too late in the afternoon, especially with a sustained-release formulation.

When starting a patient on stimulants, begin with a 12-hour day and titrate the dosage—usually up, sometimes down—depending on response and side effects. Educating patients about their medications enables them to participate in decision-making.

Common side effects of stimulants include insomnia, decreased appetite, upset stomach, headache, anxiety, agitation, and increased pulse rate and blood pressure. The increase in blood pressure is usually less than 10%, but patients with poorly controlled hypertension should not be treated with stimulants until their blood pressure is well controlled. Until more is known about long-term effects, periodic assessment of blood pressure may be warranted.

Table 2

STIMULANT THERAPY FOR ADULTS WITH ADHD

StimulantsStarting dosageTitration rateUsual dosing intervalMaximum dosage in adults
Methylphenidate
Short-acting
d, l-methylphenidate (Ritalin, Methylin)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 3 to 4 hours Usually bid-tidAverage oral dosage 0.92 mg/kg/d; best response to 1.0 mg/kg/d16
Intermediate-acting
d, l-methylphenidate (Ritalin SR, Metadate ER, Methylin ER)20 mg Ritalin SR; 10 mg Methylin ER or Metadate ER10 to 20 mg per weekqd to bid 
d-methylphenidate (Focalin)2.5 mg bid2.5 to 5 mg per weekbid, at least 4 hours apart 
Long-acting
d, l-methylphenidate (Concerta)18 mg qd18 mg every 3 to 5 days12+ hours, usually qd 
d, l-methylphenidate (Metadate CD)20 mg qd20 mg per weekqd 
Amphetamine
Short-acting
(Dexedrine, Dextrostat)2.5 to 5 mg qd2.5 to 5 mg every 3 to 5 daysEvery 4 to 6 hours Usually bid-tid 
Intermediate-acting
Mixed salts (Adderall)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 4 to 6 hours Usually qd to bidAverage dosage 54 mg/d divided in two doses; maximum 30 mg bid
(Dexedrine Spansule)5 or 10 mg qd5 mg per weekqd 
Long-acting
(Adderall XR)10 mg qd10 mg per weekqd 
Stimulant
Pemoline (Cylert)37.5 mg qd18.75 mg per weekqd; typical range 56.25 to 75 mg qdMaximum dosage 112.5 mg/d

Box 2

NONDRUG THERAPIES FOR ADULTS WITH ADHD

  • Organized and orderly home and working environment
  • Designated work/study space at home
  • Designated coach to supervise work/study
  • Healthy meals at regularly scheduled times
  • Regular exercise

Adults with ADHD have been treated with mixed amphetamine salts with positive results. In a 7-week controlled, crossover study, 27 adults with ADHD received an average of 54 mg/d administered in two doses. Symptoms improved significantly—a 42% decrease on the ADHD Rating Scale. The medication was well-tolerated, and 70% of those receiving mixed amphetamine salts improved, compared with 7% of those who received a placebo.4

Duration of action of mixed salts of amphetamine has been measured at 3.5 hours with a 5-mg dose and 6.4 hours with a 20-mg dose.5 With methylphenidate, a dose of 12.5 mg worked for 4 hours. The maximum recommended dosage of mixed salts of amphetamine is 40 mg/d in divided doses.

Stimulant medications are well-tolerated. Addiction and the need for increased dosages can occur over long-term use (months to years). Reducing the dosage or switching from methylphenidate to an amphetamine variant can usually prevent these problems.

The FDA recently approved a single-enantiomer form of methylphenidate. It contains only the active “d” enantiomer, whereas the racemic mixture contains both the “d” and “l” enantiomers. Because the “l” enantiomer is inert, the resulting medication is more potent and may be prescribed at half the dosage of the racemic mixture.

Pemoline, a once-daily stimulant, is considered a second-line treatment because of reports of hepatic failure in some patients. Its use requires written informed consent and liver function tests at baseline and every 2 weeks. In a controlled trial, pemoline at high dosages (120 to 160 mg/d) was found moderately effective in adults with ADHD.6

Newer options: Longer-acting stimulants

Newer forms of slow-release methylphenidate and mixed amphetamine salts with sophisticated delivery systems are available.

Metadate CD is delivered in capsules containing beads with polymer coatings that dissolve and release their contents at different times. The capsules contain a 30:70 ratio of immediate- and extended-release beads.

Metadate CD has not been tested for adults in controlled clinical trials. In children ages 6 to 15, a single morning dose has been shown to be clinically effective in the morning and afternoon. A supplemental immediate-release capsule can be given in the morning if a patient’s medication levels need to be increased quickly. Dosage supplementation may also be required later in the day.

 

 

Concerta is delivered in 18-mg and 36-mg tablets. The immediate-release coating on the tablets delivers medication within the first hour. The drug inside then dissolves in the GI tract and is released at a controlled rate by osmotic pressure. The indigestible tablet is passed in the stool.

Concerta was investigated in children ages 6 to 12 and provides 10 to 12 hours of sustained medication. From child studies, we know that when a patient takes a 36-mg tablet at 6 AM, blood levels decline in late afternoon. An 18-mg dose at noon covers the 4 to 6 hours needed for evening chores.

Adderall XR is an extended-release, once-daily form of mixed amphetamine salts. No controlled trials of this formulation are available in adults with ADHD. Its efficacy was established after two clinical trials of children aged 6 to 12 who met DSM-IV criteria for ADHD.

Individualized and flexible dosing improves symptom control and compliance when treating adults with ADHD. For some patients, once-daily dosing is more convenient than multiple doses, while others prefer the immediate-release form because they like its midday “pause” and bid dosing. The immediate-release tablet allows the flexibility of bid or tid dosing, depending on the day’s requirements.

Antidepressants: Another choice

Antidepressants are usually considered second-line treatment for ADHD because of concerns about efficacy and side effects. The few available studies show antidepressants work as well as stimulants but more slowly. It is good practice, therefore, to advise patients that—unlike feeling the effect of a stimulant in 60 minutes—they will not feel an effect from an antidepressant for days or weeks, and that achieving an optimal effect may take 4 to 6 weeks.

Antidepressants have several advantages over stimulants. They are not classified as narcotics, work without the on-off effects of stimulants, and can treat comorbid depression and anxiety. For adult ADHD, the most effective agents work on the catecholamine systems—norepinephrine and/or dopamine. This includes the tricyclic antidepressants, MAO inhibitors, bupropion, and venlafaxine. The serotonin reuptake inhibitors have not shown promise in ADHD, nor have mirtazapine or nefazodone demonstrated much effect.

Desipramine, a tricyclic antidepressant, is a strong inhibitor of norepinephrine reuptake. In a double-blind, controlled study in 41 adults with ADHD, 68% of patients receiving desipramine, 200 mg/d, responded positively, compared with no patients who took a placebo.7

When venlafaxine was given in standard dosages to 10 adults with ADHD in an open, 8-week clinical trial, an effect was seen by week two. Of the nine patients who completed the study, seven were considered responders. Symptoms were reduced significantly with venlafaxine treatment, and most side effects were mild.8

In an open study, bupropion treatment resulted in moderate to marked response in 74% of 19 patients. Ten of those patients who responded chose to continue bupropion rather than their previous medication.9 In a 6-week controlled study of 40 patients, bupropion use was associated with a 42% reduction in ADHD symptoms in the 38 patients who completed the study. Patients who received a placebo showed only a 24% reduction in symptoms. According to the CGI, 52% of patients who received bupropion reported being “much improved” or “very improved” compared with 11% of those receiving a placebo.10

Other treatment options that have shown mixed results include modafinil, alpha-2a agonists, acetylcholinesterase inhibitors, and the histaminergic agents.

Managing adverse effects

Substance abuse Stimulant abuse has been a concern, but it has not become the problem many feared. In fact, some studies have found that methylphenidate may help stanch the craving for cocaine in adults with ADHD.11,12 Treating ADHD with pharmacotherapy also has been shown to reduce the risk for substance abuse in adolescence by 85%.13

With careful screening, you can usually identify drug-seeking behavior in adult patients. For patients with substance abuse problems, you can prescribe the nonstimulants.

Tics that can occur with stimulant medications usually can be suppressed by reducing the dosage, being vigilant, and waiting it out. Tics may ameliorate over weeks to months.

Cardiac and cognitive effects Long-term use of stimulant medications at high dosages has been associated with cardiac and cognitive toxicity, as noted in the 1998 NIH consensus statement on diagnosis and treatment of ADHD. It is important to provide patients with this information as part of their informed-consent briefing. (See “Related resources,” to view the consensus statement.)

Nonpharmacologic management

Nonpharmacologic treatments such as EEG biofeedback; psychoeducational approaches; and individual, family, and group psychotherapy are widely used to treat adults with ADHD. Clinicians and patients often perceive these interventions as beneficial, although none have been tested in randomized, placebo-controlled studies.

 

 

Patients often function better when their home and work environments are thoughtfully organized, with a designated work/study space and regularly scheduled times for meals, sleep, and exercise. An ADHD coach may facilitate such structure and discipline (Box 2).

New agents in the pipeline

Efforts are being made to increase awareness of adult ADHD and to improve its treatment. For example, the National Institute of Mental Health is funding research on adult ADHD and displays on its Web site a PET scan of an adult brain with ADHD (see “Related resources”).14 Several medications also are being developed to treat ADHD.

Atomoxetine, a nonstimulant medication awaiting FDA approval for adult ADHD, is a selective norepinephrine reuptake inhibitor. In a double-blind, placebo-controlled, crossover study of adults with well-characterized ADHD, 11 of 21 patients improved with use of atomoxetine, compared with 2 of 21 who improved with use of a placebo. The average dosage of 76 mg/d was well-tolerated.15 The 52% response rate is similar to the 54% average improvement rate reported for methylphenidate in previous studies of adult ADHD.

In clinical trials, atomoxetine was given bid. Insomnia was not a side effect, so bid dosing does not interfere with sleep. Approximately 10 to 15% of patients experienced weight loss as a side effect.

Other treatment options under development include:

  • a transdermal system for delivery of methylphenidate16
  • a novel nicotinic analogue
  • glutamate AMPA receptor modulation
  • omega-3 fatty acids.

Related resources

  • Hallowell EM, Ratey JJ. Driven to distraction: Recognizing and coping with attention deficit disorder from childhood through adulthood. New York: Simon and Schuster; Reprint edition 1995.
  • Solanto MV, Arnstein AFT, Castellanos FX, eds. Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press; 2001.
  • Weiss M, Trokenberg-Hechtman L, Weiss G. ADHD in adulthood: A guide to current theory, diagnosis, and treatment. Baltimore: Johns Hopkins University Press; 1999.
  • National Institute of Mental Health. http://www.nimh.nih.gov

Drug brand names

  • Atomoxetine • (investigational)
  • Bupropion • Wellbutrin
  • Desipramine • Norpramin
  • Dextroamphetamine • Dexedrine, Dextrostat
  • Methamphetamine • Desoxyn
  • Methylphenidate • Focalin, Ritalin
  • Methylphenidate SR • Concerta, Metadate CD, Metadate ER, Methylin ER, Ritalin SR
  • Mixed salts of amphetamine • Adderall, Adderall XR
  • Modafinil • Provigil
  • Pemoline • Cylert
  • Venlafaxine • Effexor

Disclosure

The author reports that he serves as a consultant to Eli Lilly and Company and is on the speaker’s bureaus of Wyeth Pharmaceuticals and AstraZeneca.

Attention-deficit/hyperactivity disorder (ADHD) may be the only mental disorder that was discovered in children and later acknowledged in adults. Although controlled studies of adults with ADHD are few, we know that ADHD is common in adults, it can be diagnosed reliably, and 75% of those treated respond to treatment.1

The hallmark symptom of ADHD in children—hyperactivity—is usually attenuated in adults. In fact, some adults prefer the term ADD to ADHD because they are not hyperactive. This may be especially true of women, as their attention problems during childhood often were not recognized as ADHD (Box 1).

Box 1

WHY ADHD IS OFTEN MISSED IN GIRLS

In childhood, girls with ADHD typically present with attention problems and over-talkativeness, rather than hyperactivity. Talking too much does not disrupt the classroom as much as the larger-scale misbehavior of boys with ADHD, so the diagnosis is often missed in these girls. Overtalkativeness was added to the DSM-III-R criteria for ADHD in 1987, after it was recognized as a symptom of overactivity.

Now in midlife, many women with undiagnosed ADHD have children with ADHD. As they bring their children to treatment, these women are recognizing similar attention deficit symptoms from their own childhoods and are getting the help they need. As adults, many have low self-esteem, low energy, and weight problems. Among adults with ADHD, these women may be the most underdiagnosed.

Characteristics of adult ADHD

Adults with ADHD visit a psychiatrist for a variety of reasons. Often they are parents of children diagnosed with ADHD, and the possibility that they are similarly affected has arisen during their children’s evaluation and treatment. Sometimes they have recognized themselves in consumer articles about ADHD, or others have seen them in this light.

Adults with ADHD continue to experience their childhood difficulties in sustaining attention, listening, following instructions, and organizing tasks; inattention to details; lack of sustained mental effort; losing things; distractibility, and forgetfulness. Typical complaints include underachievement and poor adjustment at work or home. Comorbid ADHD may also be identified in patients who present with depression, anxiety, substance misuse, and mood swings.

The cognitive impairment of ADHD continues into adulthood, even in adults without hyperactive symptoms. It may be that adults are not hyperactive because the basal ganglia, which control motor activity in the brain, have over the years accommodated the problem through behavior modification or neurodevelopmental changes in late adolescence.2

Children with ADHD have abnormal cerebrospinal fluid (CSF) and blood levels of the dopaminergic metabolite homovanillic acid (HVA), but adults with ADHD may not. The primary origin for CSF HVA is the nigrostriatum, which suggests that subcortical dopaminergic nuclei are more often affected in children than adults.2 This may mean that compensatory changes occur as persons with ADHD mature, or perhaps the forms of ADHD that persist into adulthood have a different pathology or pathophysiology.

Comorbidities with ADHD

Rarely does one see pure ADHD; comorbidity is the rule. ADHD can be diagnosed quickly if you know what to look for. But a facile diagnosis may overlook a comorbidity that must be treated first—especially if you plan to use stimulants. Many patients with ADHD also have bipolar disorder, and a smaller proportion of patients with bipolar disorder have undetected ADHD. Placing a patient with undetected bipolar disorder on a stimulant could precipitate mania.

Table 1

COMMON COMORBIDITIES WITH ADHD

Bipolar disorder
Anxiety disorder
Depression
Drug dependence
Personality disorders
Somatoform disorders
Tourette’s disorder
Obsessive-compulsive disorder
Intermittent explosive disorder
Impulse control problems
 Addictive behaviors
 Sexual problems
 Compulsive gambling
Learning disabilities
Asperger’s syndrome

From the initial assessment, your treatment plan must address comorbid conditions (Table 1). This means taking a good history that includes corroborating information from relatives and data from the past, if possible. The case will then be much easier to manage, and quality of care greatly enhanced.

Stimulants: Usual first-choice therapy

In most cases, adult ADHD responds well to stimulant medications, although most available evidence is limited to studies in children. Several nonstimulant medications are also available, and the FDA is considering a new-drug application for a medication indicated for adult ADHD. Stimulants produce significant improvement in 30% of patients and mixed results in another 40%. Comorbidities may account for the 10 to 30% of patients who do not respond to stimulant therapy.

Methylphenidate, taken multiple times daily, is the most common treatment for ADHD. Dextroamphetamine and mixed salts of amphetamine also are used (Table 2).3 Patients usually respond to either methylphenidate or an amphetamine, and typically 25% of those who do not respond to one will respond to the other. When the clinical efficacy of amphetamines diminishes over time, many psychiatrists rotate medications. Replacing one amphetamine with another often eliminates the need to slowly increase the dosage and allows the clinician to maintain a relatively stable regimen.

 

 

When administering stimulants to adults, consider the individual’s total dosage requirement and daily schedule. Will he or she fare better with multiple daily dosing or a sustained-release form? How long is his or her average day? Does the patient have to be alert for 12 hours—or longer?

Some patients cannot sleep unless they take their last stimulant dose at bedtime. Others will have insomnia if a last dose is taken too late in the afternoon, especially with a sustained-release formulation.

When starting a patient on stimulants, begin with a 12-hour day and titrate the dosage—usually up, sometimes down—depending on response and side effects. Educating patients about their medications enables them to participate in decision-making.

Common side effects of stimulants include insomnia, decreased appetite, upset stomach, headache, anxiety, agitation, and increased pulse rate and blood pressure. The increase in blood pressure is usually less than 10%, but patients with poorly controlled hypertension should not be treated with stimulants until their blood pressure is well controlled. Until more is known about long-term effects, periodic assessment of blood pressure may be warranted.

Table 2

STIMULANT THERAPY FOR ADULTS WITH ADHD

StimulantsStarting dosageTitration rateUsual dosing intervalMaximum dosage in adults
Methylphenidate
Short-acting
d, l-methylphenidate (Ritalin, Methylin)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 3 to 4 hours Usually bid-tidAverage oral dosage 0.92 mg/kg/d; best response to 1.0 mg/kg/d16
Intermediate-acting
d, l-methylphenidate (Ritalin SR, Metadate ER, Methylin ER)20 mg Ritalin SR; 10 mg Methylin ER or Metadate ER10 to 20 mg per weekqd to bid 
d-methylphenidate (Focalin)2.5 mg bid2.5 to 5 mg per weekbid, at least 4 hours apart 
Long-acting
d, l-methylphenidate (Concerta)18 mg qd18 mg every 3 to 5 days12+ hours, usually qd 
d, l-methylphenidate (Metadate CD)20 mg qd20 mg per weekqd 
Amphetamine
Short-acting
(Dexedrine, Dextrostat)2.5 to 5 mg qd2.5 to 5 mg every 3 to 5 daysEvery 4 to 6 hours Usually bid-tid 
Intermediate-acting
Mixed salts (Adderall)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 4 to 6 hours Usually qd to bidAverage dosage 54 mg/d divided in two doses; maximum 30 mg bid
(Dexedrine Spansule)5 or 10 mg qd5 mg per weekqd 
Long-acting
(Adderall XR)10 mg qd10 mg per weekqd 
Stimulant
Pemoline (Cylert)37.5 mg qd18.75 mg per weekqd; typical range 56.25 to 75 mg qdMaximum dosage 112.5 mg/d

Box 2

NONDRUG THERAPIES FOR ADULTS WITH ADHD

  • Organized and orderly home and working environment
  • Designated work/study space at home
  • Designated coach to supervise work/study
  • Healthy meals at regularly scheduled times
  • Regular exercise

Adults with ADHD have been treated with mixed amphetamine salts with positive results. In a 7-week controlled, crossover study, 27 adults with ADHD received an average of 54 mg/d administered in two doses. Symptoms improved significantly—a 42% decrease on the ADHD Rating Scale. The medication was well-tolerated, and 70% of those receiving mixed amphetamine salts improved, compared with 7% of those who received a placebo.4

Duration of action of mixed salts of amphetamine has been measured at 3.5 hours with a 5-mg dose and 6.4 hours with a 20-mg dose.5 With methylphenidate, a dose of 12.5 mg worked for 4 hours. The maximum recommended dosage of mixed salts of amphetamine is 40 mg/d in divided doses.

Stimulant medications are well-tolerated. Addiction and the need for increased dosages can occur over long-term use (months to years). Reducing the dosage or switching from methylphenidate to an amphetamine variant can usually prevent these problems.

The FDA recently approved a single-enantiomer form of methylphenidate. It contains only the active “d” enantiomer, whereas the racemic mixture contains both the “d” and “l” enantiomers. Because the “l” enantiomer is inert, the resulting medication is more potent and may be prescribed at half the dosage of the racemic mixture.

Pemoline, a once-daily stimulant, is considered a second-line treatment because of reports of hepatic failure in some patients. Its use requires written informed consent and liver function tests at baseline and every 2 weeks. In a controlled trial, pemoline at high dosages (120 to 160 mg/d) was found moderately effective in adults with ADHD.6

Newer options: Longer-acting stimulants

Newer forms of slow-release methylphenidate and mixed amphetamine salts with sophisticated delivery systems are available.

Metadate CD is delivered in capsules containing beads with polymer coatings that dissolve and release their contents at different times. The capsules contain a 30:70 ratio of immediate- and extended-release beads.

Metadate CD has not been tested for adults in controlled clinical trials. In children ages 6 to 15, a single morning dose has been shown to be clinically effective in the morning and afternoon. A supplemental immediate-release capsule can be given in the morning if a patient’s medication levels need to be increased quickly. Dosage supplementation may also be required later in the day.

 

 

Concerta is delivered in 18-mg and 36-mg tablets. The immediate-release coating on the tablets delivers medication within the first hour. The drug inside then dissolves in the GI tract and is released at a controlled rate by osmotic pressure. The indigestible tablet is passed in the stool.

Concerta was investigated in children ages 6 to 12 and provides 10 to 12 hours of sustained medication. From child studies, we know that when a patient takes a 36-mg tablet at 6 AM, blood levels decline in late afternoon. An 18-mg dose at noon covers the 4 to 6 hours needed for evening chores.

Adderall XR is an extended-release, once-daily form of mixed amphetamine salts. No controlled trials of this formulation are available in adults with ADHD. Its efficacy was established after two clinical trials of children aged 6 to 12 who met DSM-IV criteria for ADHD.

Individualized and flexible dosing improves symptom control and compliance when treating adults with ADHD. For some patients, once-daily dosing is more convenient than multiple doses, while others prefer the immediate-release form because they like its midday “pause” and bid dosing. The immediate-release tablet allows the flexibility of bid or tid dosing, depending on the day’s requirements.

Antidepressants: Another choice

Antidepressants are usually considered second-line treatment for ADHD because of concerns about efficacy and side effects. The few available studies show antidepressants work as well as stimulants but more slowly. It is good practice, therefore, to advise patients that—unlike feeling the effect of a stimulant in 60 minutes—they will not feel an effect from an antidepressant for days or weeks, and that achieving an optimal effect may take 4 to 6 weeks.

Antidepressants have several advantages over stimulants. They are not classified as narcotics, work without the on-off effects of stimulants, and can treat comorbid depression and anxiety. For adult ADHD, the most effective agents work on the catecholamine systems—norepinephrine and/or dopamine. This includes the tricyclic antidepressants, MAO inhibitors, bupropion, and venlafaxine. The serotonin reuptake inhibitors have not shown promise in ADHD, nor have mirtazapine or nefazodone demonstrated much effect.

Desipramine, a tricyclic antidepressant, is a strong inhibitor of norepinephrine reuptake. In a double-blind, controlled study in 41 adults with ADHD, 68% of patients receiving desipramine, 200 mg/d, responded positively, compared with no patients who took a placebo.7

When venlafaxine was given in standard dosages to 10 adults with ADHD in an open, 8-week clinical trial, an effect was seen by week two. Of the nine patients who completed the study, seven were considered responders. Symptoms were reduced significantly with venlafaxine treatment, and most side effects were mild.8

In an open study, bupropion treatment resulted in moderate to marked response in 74% of 19 patients. Ten of those patients who responded chose to continue bupropion rather than their previous medication.9 In a 6-week controlled study of 40 patients, bupropion use was associated with a 42% reduction in ADHD symptoms in the 38 patients who completed the study. Patients who received a placebo showed only a 24% reduction in symptoms. According to the CGI, 52% of patients who received bupropion reported being “much improved” or “very improved” compared with 11% of those receiving a placebo.10

Other treatment options that have shown mixed results include modafinil, alpha-2a agonists, acetylcholinesterase inhibitors, and the histaminergic agents.

Managing adverse effects

Substance abuse Stimulant abuse has been a concern, but it has not become the problem many feared. In fact, some studies have found that methylphenidate may help stanch the craving for cocaine in adults with ADHD.11,12 Treating ADHD with pharmacotherapy also has been shown to reduce the risk for substance abuse in adolescence by 85%.13

With careful screening, you can usually identify drug-seeking behavior in adult patients. For patients with substance abuse problems, you can prescribe the nonstimulants.

Tics that can occur with stimulant medications usually can be suppressed by reducing the dosage, being vigilant, and waiting it out. Tics may ameliorate over weeks to months.

Cardiac and cognitive effects Long-term use of stimulant medications at high dosages has been associated with cardiac and cognitive toxicity, as noted in the 1998 NIH consensus statement on diagnosis and treatment of ADHD. It is important to provide patients with this information as part of their informed-consent briefing. (See “Related resources,” to view the consensus statement.)

Nonpharmacologic management

Nonpharmacologic treatments such as EEG biofeedback; psychoeducational approaches; and individual, family, and group psychotherapy are widely used to treat adults with ADHD. Clinicians and patients often perceive these interventions as beneficial, although none have been tested in randomized, placebo-controlled studies.

 

 

Patients often function better when their home and work environments are thoughtfully organized, with a designated work/study space and regularly scheduled times for meals, sleep, and exercise. An ADHD coach may facilitate such structure and discipline (Box 2).

New agents in the pipeline

Efforts are being made to increase awareness of adult ADHD and to improve its treatment. For example, the National Institute of Mental Health is funding research on adult ADHD and displays on its Web site a PET scan of an adult brain with ADHD (see “Related resources”).14 Several medications also are being developed to treat ADHD.

Atomoxetine, a nonstimulant medication awaiting FDA approval for adult ADHD, is a selective norepinephrine reuptake inhibitor. In a double-blind, placebo-controlled, crossover study of adults with well-characterized ADHD, 11 of 21 patients improved with use of atomoxetine, compared with 2 of 21 who improved with use of a placebo. The average dosage of 76 mg/d was well-tolerated.15 The 52% response rate is similar to the 54% average improvement rate reported for methylphenidate in previous studies of adult ADHD.

In clinical trials, atomoxetine was given bid. Insomnia was not a side effect, so bid dosing does not interfere with sleep. Approximately 10 to 15% of patients experienced weight loss as a side effect.

Other treatment options under development include:

  • a transdermal system for delivery of methylphenidate16
  • a novel nicotinic analogue
  • glutamate AMPA receptor modulation
  • omega-3 fatty acids.

Related resources

  • Hallowell EM, Ratey JJ. Driven to distraction: Recognizing and coping with attention deficit disorder from childhood through adulthood. New York: Simon and Schuster; Reprint edition 1995.
  • Solanto MV, Arnstein AFT, Castellanos FX, eds. Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press; 2001.
  • Weiss M, Trokenberg-Hechtman L, Weiss G. ADHD in adulthood: A guide to current theory, diagnosis, and treatment. Baltimore: Johns Hopkins University Press; 1999.
  • National Institute of Mental Health. http://www.nimh.nih.gov

Drug brand names

  • Atomoxetine • (investigational)
  • Bupropion • Wellbutrin
  • Desipramine • Norpramin
  • Dextroamphetamine • Dexedrine, Dextrostat
  • Methamphetamine • Desoxyn
  • Methylphenidate • Focalin, Ritalin
  • Methylphenidate SR • Concerta, Metadate CD, Metadate ER, Methylin ER, Ritalin SR
  • Mixed salts of amphetamine • Adderall, Adderall XR
  • Modafinil • Provigil
  • Pemoline • Cylert
  • Venlafaxine • Effexor

Disclosure

The author reports that he serves as a consultant to Eli Lilly and Company and is on the speaker’s bureaus of Wyeth Pharmaceuticals and AstraZeneca.

References

1. Gadrow KD, Weiss M. Attention-deficit/hyperactivity disorder in adults: beyond controversy. Arch Gen Psychiatry 2001;58(8):784-5.

2. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998;18(15):5901-7.

3. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43.

4. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58(8):775-82.

5. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34(1):55-60.

6. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19(3):257-64.

7. Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995;183(1):48-50.

8. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57(5):184-9.

9. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147(8):1018-20.

10. Wilens TE, Spencer TJ, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158(2):282-8.

11. Grabowski J, Roache JD, Schmitz JM, Rhoades H, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17(6):485-8.

12. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59(6):300-5.

13. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104(2):e20.-

14. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 1990;323(20):1361-6.

15. Spencer T, Biederman J, Wilens T. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155(5):693-5.

16. Noven Pharmaceuticals. The Science of Noven. Research and development. Transdermal technology. Available at: http://www.noven.com/research.htm.

References

1. Gadrow KD, Weiss M. Attention-deficit/hyperactivity disorder in adults: beyond controversy. Arch Gen Psychiatry 2001;58(8):784-5.

2. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998;18(15):5901-7.

3. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43.

4. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58(8):775-82.

5. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34(1):55-60.

6. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19(3):257-64.

7. Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995;183(1):48-50.

8. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57(5):184-9.

9. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147(8):1018-20.

10. Wilens TE, Spencer TJ, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158(2):282-8.

11. Grabowski J, Roache JD, Schmitz JM, Rhoades H, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17(6):485-8.

12. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59(6):300-5.

13. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104(2):e20.-

14. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 1990;323(20):1361-6.

15. Spencer T, Biederman J, Wilens T. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155(5):693-5.

16. Noven Pharmaceuticals. The Science of Noven. Research and development. Transdermal technology. Available at: http://www.noven.com/research.htm.

Issue
Current Psychiatry - 01(10)
Issue
Current Psychiatry - 01(10)
Page Number
34-43
Page Number
34-43
Publications
Publications
Topics
Article Type
Display Headline
Adult ADHD: Less hyperactivity, but lingering inattention and distress
Display Headline
Adult ADHD: Less hyperactivity, but lingering inattention and distress
Sections
Article Source

PURLs Copyright

Inside the Article

Adult ADHD: Less hyperactivity, but lingering inattention and distress

Article Type
Changed
Tue, 12/11/2018 - 15:12
Display Headline
Adult ADHD: Less hyperactivity, but lingering inattention and distress

Attention-deficit/hyperactivity disorder (ADHD) may be the only mental disorder that was discovered in children and later acknowledged in adults. Although controlled studies of adults with ADHD are few, we know that ADHD is common in adults, it can be diagnosed reliably, and 75% of those treated respond to treatment.1

The hallmark symptom of ADHD in children—hyperactivity—is usually attenuated in adults. In fact, some adults prefer the term ADD to ADHD because they are not hyperactive. This may be especially true of women, as their attention problems during childhood often were not recognized as ADHD (Box 1).

Box 1

WHY ADHD IS OFTEN MISSED IN GIRLS

In childhood, girls with ADHD typically present with attention problems and over-talkativeness, rather than hyperactivity. Talking too much does not disrupt the classroom as much as the larger-scale misbehavior of boys with ADHD, so the diagnosis is often missed in these girls. Overtalkativeness was added to the DSM-III-R criteria for ADHD in 1987, after it was recognized as a symptom of overactivity.

Now in midlife, many women with undiagnosed ADHD have children with ADHD. As they bring their children to treatment, these women are recognizing similar attention deficit symptoms from their own childhoods and are getting the help they need. As adults, many have low self-esteem, low energy, and weight problems. Among adults with ADHD, these women may be the most underdiagnosed.

Characteristics of adult ADHD

Adults with ADHD visit a psychiatrist for a variety of reasons. Often they are parents of children diagnosed with ADHD, and the possibility that they are similarly affected has arisen during their children’s evaluation and treatment. Sometimes they have recognized themselves in consumer articles about ADHD, or others have seen them in this light.

Adults with ADHD continue to experience their childhood difficulties in sustaining attention, listening, following instructions, and organizing tasks; inattention to details; lack of sustained mental effort; losing things; distractibility, and forgetfulness. Typical complaints include underachievement and poor adjustment at work or home. Comorbid ADHD may also be identified in patients who present with depression, anxiety, substance misuse, and mood swings.

The cognitive impairment of ADHD continues into adulthood, even in adults without hyperactive symptoms. It may be that adults are not hyperactive because the basal ganglia, which control motor activity in the brain, have over the years accommodated the problem through behavior modification or neurodevelopmental changes in late adolescence.2

Children with ADHD have abnormal cerebrospinal fluid (CSF) and blood levels of the dopaminergic metabolite homovanillic acid (HVA), but adults with ADHD may not. The primary origin for CSF HVA is the nigrostriatum, which suggests that subcortical dopaminergic nuclei are more often affected in children than adults.2 This may mean that compensatory changes occur as persons with ADHD mature, or perhaps the forms of ADHD that persist into adulthood have a different pathology or pathophysiology.

Comorbidities with ADHD

Rarely does one see pure ADHD; comorbidity is the rule. ADHD can be diagnosed quickly if you know what to look for. But a facile diagnosis may overlook a comorbidity that must be treated first—especially if you plan to use stimulants. Many patients with ADHD also have bipolar disorder, and a smaller proportion of patients with bipolar disorder have undetected ADHD. Placing a patient with undetected bipolar disorder on a stimulant could precipitate mania.

Table 1

COMMON COMORBIDITIES WITH ADHD

Bipolar disorder
Anxiety disorder
Depression
Drug dependence
Personality disorders
Somatoform disorders
Tourette’s disorder
Obsessive-compulsive disorder
Intermittent explosive disorder
Impulse control problems
 Addictive behaviors
 Sexual problems
 Compulsive gambling
Learning disabilities
Asperger’s syndrome

From the initial assessment, your treatment plan must address comorbid conditions (Table 1). This means taking a good history that includes corroborating information from relatives and data from the past, if possible. The case will then be much easier to manage, and quality of care greatly enhanced.

Stimulants: Usual first-choice therapy

In most cases, adult ADHD responds well to stimulant medications, although most available evidence is limited to studies in children. Several nonstimulant medications are also available, and the FDA is considering a new-drug application for a medication indicated for adult ADHD. Stimulants produce significant improvement in 30% of patients and mixed results in another 40%. Comorbidities may account for the 10 to 30% of patients who do not respond to stimulant therapy.

Methylphenidate, taken multiple times daily, is the most common treatment for ADHD. Dextroamphetamine and mixed salts of amphetamine also are used (Table 2).3 Patients usually respond to either methylphenidate or an amphetamine, and typically 25% of those who do not respond to one will respond to the other. When the clinical efficacy of amphetamines diminishes over time, many psychiatrists rotate medications. Replacing one amphetamine with another often eliminates the need to slowly increase the dosage and allows the clinician to maintain a relatively stable regimen.

 

 

When administering stimulants to adults, consider the individual’s total dosage requirement and daily schedule. Will he or she fare better with multiple daily dosing or a sustained-release form? How long is his or her average day? Does the patient have to be alert for 12 hours—or longer?

Some patients cannot sleep unless they take their last stimulant dose at bedtime. Others will have insomnia if a last dose is taken too late in the afternoon, especially with a sustained-release formulation.

When starting a patient on stimulants, begin with a 12-hour day and titrate the dosage—usually up, sometimes down—depending on response and side effects. Educating patients about their medications enables them to participate in decision-making.

Common side effects of stimulants include insomnia, decreased appetite, upset stomach, headache, anxiety, agitation, and increased pulse rate and blood pressure. The increase in blood pressure is usually less than 10%, but patients with poorly controlled hypertension should not be treated with stimulants until their blood pressure is well controlled. Until more is known about long-term effects, periodic assessment of blood pressure may be warranted.

Table 2

STIMULANT THERAPY FOR ADULTS WITH ADHD

StimulantsStarting dosageTitration rateUsual dosing intervalMaximum dosage in adults
Methylphenidate
Short-acting
d, l-methylphenidate (Ritalin, Methylin)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 3 to 4 hours Usually bid-tidAverage oral dosage 0.92 mg/kg/d; best response to 1.0 mg/kg/d16
Intermediate-acting
d, l-methylphenidate (Ritalin SR, Metadate ER, Methylin ER)20 mg Ritalin SR; 10 mg Methylin ER or Metadate ER10 to 20 mg per weekqd to bid 
d-methylphenidate (Focalin)2.5 mg bid2.5 to 5 mg per weekbid, at least 4 hours apart 
Long-acting
d, l-methylphenidate (Concerta)18 mg qd18 mg every 3 to 5 days12+ hours, usually qd 
d, l-methylphenidate (Metadate CD)20 mg qd20 mg per weekqd 
Amphetamine
Short-acting
(Dexedrine, Dextrostat)2.5 to 5 mg qd2.5 to 5 mg every 3 to 5 daysEvery 4 to 6 hours Usually bid-tid 
Intermediate-acting
Mixed salts (Adderall)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 4 to 6 hours Usually qd to bidAverage dosage 54 mg/d divided in two doses; maximum 30 mg bid
(Dexedrine Spansule)5 or 10 mg qd5 mg per weekqd 
Long-acting
(Adderall XR)10 mg qd10 mg per weekqd 
Stimulant
Pemoline (Cylert)37.5 mg qd18.75 mg per weekqd; typical range 56.25 to 75 mg qdMaximum dosage 112.5 mg/d

Box 2

NONDRUG THERAPIES FOR ADULTS WITH ADHD

  • Organized and orderly home and working environment
  • Designated work/study space at home
  • Designated coach to supervise work/study
  • Healthy meals at regularly scheduled times
  • Regular exercise

Adults with ADHD have been treated with mixed amphetamine salts with positive results. In a 7-week controlled, crossover study, 27 adults with ADHD received an average of 54 mg/d administered in two doses. Symptoms improved significantly—a 42% decrease on the ADHD Rating Scale. The medication was well-tolerated, and 70% of those receiving mixed amphetamine salts improved, compared with 7% of those who received a placebo.4

Duration of action of mixed salts of amphetamine has been measured at 3.5 hours with a 5-mg dose and 6.4 hours with a 20-mg dose.5 With methylphenidate, a dose of 12.5 mg worked for 4 hours. The maximum recommended dosage of mixed salts of amphetamine is 40 mg/d in divided doses.

Stimulant medications are well-tolerated. Addiction and the need for increased dosages can occur over long-term use (months to years). Reducing the dosage or switching from methylphenidate to an amphetamine variant can usually prevent these problems.

The FDA recently approved a single-enantiomer form of methylphenidate. It contains only the active “d” enantiomer, whereas the racemic mixture contains both the “d” and “l” enantiomers. Because the “l” enantiomer is inert, the resulting medication is more potent and may be prescribed at half the dosage of the racemic mixture.

Pemoline, a once-daily stimulant, is considered a second-line treatment because of reports of hepatic failure in some patients. Its use requires written informed consent and liver function tests at baseline and every 2 weeks. In a controlled trial, pemoline at high dosages (120 to 160 mg/d) was found moderately effective in adults with ADHD.6

Newer options: Longer-acting stimulants

Newer forms of slow-release methylphenidate and mixed amphetamine salts with sophisticated delivery systems are available.

Metadate CD is delivered in capsules containing beads with polymer coatings that dissolve and release their contents at different times. The capsules contain a 30:70 ratio of immediate- and extended-release beads.

Metadate CD has not been tested for adults in controlled clinical trials. In children ages 6 to 15, a single morning dose has been shown to be clinically effective in the morning and afternoon. A supplemental immediate-release capsule can be given in the morning if a patient’s medication levels need to be increased quickly. Dosage supplementation may also be required later in the day.

 

 

Concerta is delivered in 18-mg and 36-mg tablets. The immediate-release coating on the tablets delivers medication within the first hour. The drug inside then dissolves in the GI tract and is released at a controlled rate by osmotic pressure. The indigestible tablet is passed in the stool.

Concerta was investigated in children ages 6 to 12 and provides 10 to 12 hours of sustained medication. From child studies, we know that when a patient takes a 36-mg tablet at 6 AM, blood levels decline in late afternoon. An 18-mg dose at noon covers the 4 to 6 hours needed for evening chores.

Adderall XR is an extended-release, once-daily form of mixed amphetamine salts. No controlled trials of this formulation are available in adults with ADHD. Its efficacy was established after two clinical trials of children aged 6 to 12 who met DSM-IV criteria for ADHD.

Individualized and flexible dosing improves symptom control and compliance when treating adults with ADHD. For some patients, once-daily dosing is more convenient than multiple doses, while others prefer the immediate-release form because they like its midday “pause” and bid dosing. The immediate-release tablet allows the flexibility of bid or tid dosing, depending on the day’s requirements.

Antidepressants: Another choice

Antidepressants are usually considered second-line treatment for ADHD because of concerns about efficacy and side effects. The few available studies show antidepressants work as well as stimulants but more slowly. It is good practice, therefore, to advise patients that—unlike feeling the effect of a stimulant in 60 minutes—they will not feel an effect from an antidepressant for days or weeks, and that achieving an optimal effect may take 4 to 6 weeks.

Antidepressants have several advantages over stimulants. They are not classified as narcotics, work without the on-off effects of stimulants, and can treat comorbid depression and anxiety. For adult ADHD, the most effective agents work on the catecholamine systems—norepinephrine and/or dopamine. This includes the tricyclic antidepressants, MAO inhibitors, bupropion, and venlafaxine. The serotonin reuptake inhibitors have not shown promise in ADHD, nor have mirtazapine or nefazodone demonstrated much effect.

Desipramine, a tricyclic antidepressant, is a strong inhibitor of norepinephrine reuptake. In a double-blind, controlled study in 41 adults with ADHD, 68% of patients receiving desipramine, 200 mg/d, responded positively, compared with no patients who took a placebo.7

When venlafaxine was given in standard dosages to 10 adults with ADHD in an open, 8-week clinical trial, an effect was seen by week two. Of the nine patients who completed the study, seven were considered responders. Symptoms were reduced significantly with venlafaxine treatment, and most side effects were mild.8

In an open study, bupropion treatment resulted in moderate to marked response in 74% of 19 patients. Ten of those patients who responded chose to continue bupropion rather than their previous medication.9 In a 6-week controlled study of 40 patients, bupropion use was associated with a 42% reduction in ADHD symptoms in the 38 patients who completed the study. Patients who received a placebo showed only a 24% reduction in symptoms. According to the CGI, 52% of patients who received bupropion reported being “much improved” or “very improved” compared with 11% of those receiving a placebo.10

Other treatment options that have shown mixed results include modafinil, alpha-2a agonists, acetylcholinesterase inhibitors, and the histaminergic agents.

Managing adverse effects

Substance abuse Stimulant abuse has been a concern, but it has not become the problem many feared. In fact, some studies have found that methylphenidate may help stanch the craving for cocaine in adults with ADHD.11,12 Treating ADHD with pharmacotherapy also has been shown to reduce the risk for substance abuse in adolescence by 85%.13

With careful screening, you can usually identify drug-seeking behavior in adult patients. For patients with substance abuse problems, you can prescribe the nonstimulants.

Tics that can occur with stimulant medications usually can be suppressed by reducing the dosage, being vigilant, and waiting it out. Tics may ameliorate over weeks to months.

Cardiac and cognitive effects Long-term use of stimulant medications at high dosages has been associated with cardiac and cognitive toxicity, as noted in the 1998 NIH consensus statement on diagnosis and treatment of ADHD. It is important to provide patients with this information as part of their informed-consent briefing. (See “Related resources,” to view the consensus statement.)

Nonpharmacologic management

Nonpharmacologic treatments such as EEG biofeedback; psychoeducational approaches; and individual, family, and group psychotherapy are widely used to treat adults with ADHD. Clinicians and patients often perceive these interventions as beneficial, although none have been tested in randomized, placebo-controlled studies.

 

 

Patients often function better when their home and work environments are thoughtfully organized, with a designated work/study space and regularly scheduled times for meals, sleep, and exercise. An ADHD coach may facilitate such structure and discipline (Box 2).

New agents in the pipeline

Efforts are being made to increase awareness of adult ADHD and to improve its treatment. For example, the National Institute of Mental Health is funding research on adult ADHD and displays on its Web site a PET scan of an adult brain with ADHD (see “Related resources”).14 Several medications also are being developed to treat ADHD.

Atomoxetine, a nonstimulant medication awaiting FDA approval for adult ADHD, is a selective norepinephrine reuptake inhibitor. In a double-blind, placebo-controlled, crossover study of adults with well-characterized ADHD, 11 of 21 patients improved with use of atomoxetine, compared with 2 of 21 who improved with use of a placebo. The average dosage of 76 mg/d was well-tolerated.15 The 52% response rate is similar to the 54% average improvement rate reported for methylphenidate in previous studies of adult ADHD.

In clinical trials, atomoxetine was given bid. Insomnia was not a side effect, so bid dosing does not interfere with sleep. Approximately 10 to 15% of patients experienced weight loss as a side effect.

Other treatment options under development include:

  • a transdermal system for delivery of methylphenidate16
  • a novel nicotinic analogue
  • glutamate AMPA receptor modulation
  • omega-3 fatty acids.

Related resources

  • Hallowell EM, Ratey JJ. Driven to distraction: Recognizing and coping with attention deficit disorder from childhood through adulthood. New York: Simon and Schuster; Reprint edition 1995.
  • Solanto MV, Arnstein AFT, Castellanos FX, eds. Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press; 2001.
  • Weiss M, Trokenberg-Hechtman L, Weiss G. ADHD in adulthood: A guide to current theory, diagnosis, and treatment. Baltimore: Johns Hopkins University Press; 1999.
  • National Institute of Mental Health. http://www.nimh.nih.gov

Drug brand names

  • Atomoxetine • (investigational)
  • Bupropion • Wellbutrin
  • Desipramine • Norpramin
  • Dextroamphetamine • Dexedrine, Dextrostat
  • Methamphetamine • Desoxyn
  • Methylphenidate • Focalin, Ritalin
  • Methylphenidate SR • Concerta, Metadate CD, Metadate ER, Methylin ER, Ritalin SR
  • Mixed salts of amphetamine • Adderall, Adderall XR
  • Modafinil • Provigil
  • Pemoline • Cylert
  • Venlafaxine • Effexor

Disclosure

The author reports that he serves as a consultant to Eli Lilly and Company and is on the speaker’s bureaus of Wyeth Pharmaceuticals and AstraZeneca.

References

1. Gadrow KD, Weiss M. Attention-deficit/hyperactivity disorder in adults: beyond controversy. Arch Gen Psychiatry 2001;58(8):784-5.

2. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998;18(15):5901-7.

3. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43.

4. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58(8):775-82.

5. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34(1):55-60.

6. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19(3):257-64.

7. Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995;183(1):48-50.

8. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57(5):184-9.

9. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147(8):1018-20.

10. Wilens TE, Spencer TJ, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158(2):282-8.

11. Grabowski J, Roache JD, Schmitz JM, Rhoades H, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17(6):485-8.

12. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59(6):300-5.

13. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104(2):e20.-

14. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 1990;323(20):1361-6.

15. Spencer T, Biederman J, Wilens T. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155(5):693-5.

16. Noven Pharmaceuticals. The Science of Noven. Research and development. Transdermal technology. Available at: http://www.noven.com/research.htm.

Author and Disclosure Information

Michael Alan Schwartz, MD
Clinical professor, department of psychiatry Case Western Reserve University School of Medicine Cleveland, OH

Issue
Current Psychiatry - 01(10)
Publications
Topics
Page Number
34-43
Sections
Author and Disclosure Information

Michael Alan Schwartz, MD
Clinical professor, department of psychiatry Case Western Reserve University School of Medicine Cleveland, OH

Author and Disclosure Information

Michael Alan Schwartz, MD
Clinical professor, department of psychiatry Case Western Reserve University School of Medicine Cleveland, OH

Attention-deficit/hyperactivity disorder (ADHD) may be the only mental disorder that was discovered in children and later acknowledged in adults. Although controlled studies of adults with ADHD are few, we know that ADHD is common in adults, it can be diagnosed reliably, and 75% of those treated respond to treatment.1

The hallmark symptom of ADHD in children—hyperactivity—is usually attenuated in adults. In fact, some adults prefer the term ADD to ADHD because they are not hyperactive. This may be especially true of women, as their attention problems during childhood often were not recognized as ADHD (Box 1).

Box 1

WHY ADHD IS OFTEN MISSED IN GIRLS

In childhood, girls with ADHD typically present with attention problems and over-talkativeness, rather than hyperactivity. Talking too much does not disrupt the classroom as much as the larger-scale misbehavior of boys with ADHD, so the diagnosis is often missed in these girls. Overtalkativeness was added to the DSM-III-R criteria for ADHD in 1987, after it was recognized as a symptom of overactivity.

Now in midlife, many women with undiagnosed ADHD have children with ADHD. As they bring their children to treatment, these women are recognizing similar attention deficit symptoms from their own childhoods and are getting the help they need. As adults, many have low self-esteem, low energy, and weight problems. Among adults with ADHD, these women may be the most underdiagnosed.

Characteristics of adult ADHD

Adults with ADHD visit a psychiatrist for a variety of reasons. Often they are parents of children diagnosed with ADHD, and the possibility that they are similarly affected has arisen during their children’s evaluation and treatment. Sometimes they have recognized themselves in consumer articles about ADHD, or others have seen them in this light.

Adults with ADHD continue to experience their childhood difficulties in sustaining attention, listening, following instructions, and organizing tasks; inattention to details; lack of sustained mental effort; losing things; distractibility, and forgetfulness. Typical complaints include underachievement and poor adjustment at work or home. Comorbid ADHD may also be identified in patients who present with depression, anxiety, substance misuse, and mood swings.

The cognitive impairment of ADHD continues into adulthood, even in adults without hyperactive symptoms. It may be that adults are not hyperactive because the basal ganglia, which control motor activity in the brain, have over the years accommodated the problem through behavior modification or neurodevelopmental changes in late adolescence.2

Children with ADHD have abnormal cerebrospinal fluid (CSF) and blood levels of the dopaminergic metabolite homovanillic acid (HVA), but adults with ADHD may not. The primary origin for CSF HVA is the nigrostriatum, which suggests that subcortical dopaminergic nuclei are more often affected in children than adults.2 This may mean that compensatory changes occur as persons with ADHD mature, or perhaps the forms of ADHD that persist into adulthood have a different pathology or pathophysiology.

Comorbidities with ADHD

Rarely does one see pure ADHD; comorbidity is the rule. ADHD can be diagnosed quickly if you know what to look for. But a facile diagnosis may overlook a comorbidity that must be treated first—especially if you plan to use stimulants. Many patients with ADHD also have bipolar disorder, and a smaller proportion of patients with bipolar disorder have undetected ADHD. Placing a patient with undetected bipolar disorder on a stimulant could precipitate mania.

Table 1

COMMON COMORBIDITIES WITH ADHD

Bipolar disorder
Anxiety disorder
Depression
Drug dependence
Personality disorders
Somatoform disorders
Tourette’s disorder
Obsessive-compulsive disorder
Intermittent explosive disorder
Impulse control problems
 Addictive behaviors
 Sexual problems
 Compulsive gambling
Learning disabilities
Asperger’s syndrome

From the initial assessment, your treatment plan must address comorbid conditions (Table 1). This means taking a good history that includes corroborating information from relatives and data from the past, if possible. The case will then be much easier to manage, and quality of care greatly enhanced.

Stimulants: Usual first-choice therapy

In most cases, adult ADHD responds well to stimulant medications, although most available evidence is limited to studies in children. Several nonstimulant medications are also available, and the FDA is considering a new-drug application for a medication indicated for adult ADHD. Stimulants produce significant improvement in 30% of patients and mixed results in another 40%. Comorbidities may account for the 10 to 30% of patients who do not respond to stimulant therapy.

Methylphenidate, taken multiple times daily, is the most common treatment for ADHD. Dextroamphetamine and mixed salts of amphetamine also are used (Table 2).3 Patients usually respond to either methylphenidate or an amphetamine, and typically 25% of those who do not respond to one will respond to the other. When the clinical efficacy of amphetamines diminishes over time, many psychiatrists rotate medications. Replacing one amphetamine with another often eliminates the need to slowly increase the dosage and allows the clinician to maintain a relatively stable regimen.

 

 

When administering stimulants to adults, consider the individual’s total dosage requirement and daily schedule. Will he or she fare better with multiple daily dosing or a sustained-release form? How long is his or her average day? Does the patient have to be alert for 12 hours—or longer?

Some patients cannot sleep unless they take their last stimulant dose at bedtime. Others will have insomnia if a last dose is taken too late in the afternoon, especially with a sustained-release formulation.

When starting a patient on stimulants, begin with a 12-hour day and titrate the dosage—usually up, sometimes down—depending on response and side effects. Educating patients about their medications enables them to participate in decision-making.

Common side effects of stimulants include insomnia, decreased appetite, upset stomach, headache, anxiety, agitation, and increased pulse rate and blood pressure. The increase in blood pressure is usually less than 10%, but patients with poorly controlled hypertension should not be treated with stimulants until their blood pressure is well controlled. Until more is known about long-term effects, periodic assessment of blood pressure may be warranted.

Table 2

STIMULANT THERAPY FOR ADULTS WITH ADHD

StimulantsStarting dosageTitration rateUsual dosing intervalMaximum dosage in adults
Methylphenidate
Short-acting
d, l-methylphenidate (Ritalin, Methylin)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 3 to 4 hours Usually bid-tidAverage oral dosage 0.92 mg/kg/d; best response to 1.0 mg/kg/d16
Intermediate-acting
d, l-methylphenidate (Ritalin SR, Metadate ER, Methylin ER)20 mg Ritalin SR; 10 mg Methylin ER or Metadate ER10 to 20 mg per weekqd to bid 
d-methylphenidate (Focalin)2.5 mg bid2.5 to 5 mg per weekbid, at least 4 hours apart 
Long-acting
d, l-methylphenidate (Concerta)18 mg qd18 mg every 3 to 5 days12+ hours, usually qd 
d, l-methylphenidate (Metadate CD)20 mg qd20 mg per weekqd 
Amphetamine
Short-acting
(Dexedrine, Dextrostat)2.5 to 5 mg qd2.5 to 5 mg every 3 to 5 daysEvery 4 to 6 hours Usually bid-tid 
Intermediate-acting
Mixed salts (Adderall)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 4 to 6 hours Usually qd to bidAverage dosage 54 mg/d divided in two doses; maximum 30 mg bid
(Dexedrine Spansule)5 or 10 mg qd5 mg per weekqd 
Long-acting
(Adderall XR)10 mg qd10 mg per weekqd 
Stimulant
Pemoline (Cylert)37.5 mg qd18.75 mg per weekqd; typical range 56.25 to 75 mg qdMaximum dosage 112.5 mg/d

Box 2

NONDRUG THERAPIES FOR ADULTS WITH ADHD

  • Organized and orderly home and working environment
  • Designated work/study space at home
  • Designated coach to supervise work/study
  • Healthy meals at regularly scheduled times
  • Regular exercise

Adults with ADHD have been treated with mixed amphetamine salts with positive results. In a 7-week controlled, crossover study, 27 adults with ADHD received an average of 54 mg/d administered in two doses. Symptoms improved significantly—a 42% decrease on the ADHD Rating Scale. The medication was well-tolerated, and 70% of those receiving mixed amphetamine salts improved, compared with 7% of those who received a placebo.4

Duration of action of mixed salts of amphetamine has been measured at 3.5 hours with a 5-mg dose and 6.4 hours with a 20-mg dose.5 With methylphenidate, a dose of 12.5 mg worked for 4 hours. The maximum recommended dosage of mixed salts of amphetamine is 40 mg/d in divided doses.

Stimulant medications are well-tolerated. Addiction and the need for increased dosages can occur over long-term use (months to years). Reducing the dosage or switching from methylphenidate to an amphetamine variant can usually prevent these problems.

The FDA recently approved a single-enantiomer form of methylphenidate. It contains only the active “d” enantiomer, whereas the racemic mixture contains both the “d” and “l” enantiomers. Because the “l” enantiomer is inert, the resulting medication is more potent and may be prescribed at half the dosage of the racemic mixture.

Pemoline, a once-daily stimulant, is considered a second-line treatment because of reports of hepatic failure in some patients. Its use requires written informed consent and liver function tests at baseline and every 2 weeks. In a controlled trial, pemoline at high dosages (120 to 160 mg/d) was found moderately effective in adults with ADHD.6

Newer options: Longer-acting stimulants

Newer forms of slow-release methylphenidate and mixed amphetamine salts with sophisticated delivery systems are available.

Metadate CD is delivered in capsules containing beads with polymer coatings that dissolve and release their contents at different times. The capsules contain a 30:70 ratio of immediate- and extended-release beads.

Metadate CD has not been tested for adults in controlled clinical trials. In children ages 6 to 15, a single morning dose has been shown to be clinically effective in the morning and afternoon. A supplemental immediate-release capsule can be given in the morning if a patient’s medication levels need to be increased quickly. Dosage supplementation may also be required later in the day.

 

 

Concerta is delivered in 18-mg and 36-mg tablets. The immediate-release coating on the tablets delivers medication within the first hour. The drug inside then dissolves in the GI tract and is released at a controlled rate by osmotic pressure. The indigestible tablet is passed in the stool.

Concerta was investigated in children ages 6 to 12 and provides 10 to 12 hours of sustained medication. From child studies, we know that when a patient takes a 36-mg tablet at 6 AM, blood levels decline in late afternoon. An 18-mg dose at noon covers the 4 to 6 hours needed for evening chores.

Adderall XR is an extended-release, once-daily form of mixed amphetamine salts. No controlled trials of this formulation are available in adults with ADHD. Its efficacy was established after two clinical trials of children aged 6 to 12 who met DSM-IV criteria for ADHD.

Individualized and flexible dosing improves symptom control and compliance when treating adults with ADHD. For some patients, once-daily dosing is more convenient than multiple doses, while others prefer the immediate-release form because they like its midday “pause” and bid dosing. The immediate-release tablet allows the flexibility of bid or tid dosing, depending on the day’s requirements.

Antidepressants: Another choice

Antidepressants are usually considered second-line treatment for ADHD because of concerns about efficacy and side effects. The few available studies show antidepressants work as well as stimulants but more slowly. It is good practice, therefore, to advise patients that—unlike feeling the effect of a stimulant in 60 minutes—they will not feel an effect from an antidepressant for days or weeks, and that achieving an optimal effect may take 4 to 6 weeks.

Antidepressants have several advantages over stimulants. They are not classified as narcotics, work without the on-off effects of stimulants, and can treat comorbid depression and anxiety. For adult ADHD, the most effective agents work on the catecholamine systems—norepinephrine and/or dopamine. This includes the tricyclic antidepressants, MAO inhibitors, bupropion, and venlafaxine. The serotonin reuptake inhibitors have not shown promise in ADHD, nor have mirtazapine or nefazodone demonstrated much effect.

Desipramine, a tricyclic antidepressant, is a strong inhibitor of norepinephrine reuptake. In a double-blind, controlled study in 41 adults with ADHD, 68% of patients receiving desipramine, 200 mg/d, responded positively, compared with no patients who took a placebo.7

When venlafaxine was given in standard dosages to 10 adults with ADHD in an open, 8-week clinical trial, an effect was seen by week two. Of the nine patients who completed the study, seven were considered responders. Symptoms were reduced significantly with venlafaxine treatment, and most side effects were mild.8

In an open study, bupropion treatment resulted in moderate to marked response in 74% of 19 patients. Ten of those patients who responded chose to continue bupropion rather than their previous medication.9 In a 6-week controlled study of 40 patients, bupropion use was associated with a 42% reduction in ADHD symptoms in the 38 patients who completed the study. Patients who received a placebo showed only a 24% reduction in symptoms. According to the CGI, 52% of patients who received bupropion reported being “much improved” or “very improved” compared with 11% of those receiving a placebo.10

Other treatment options that have shown mixed results include modafinil, alpha-2a agonists, acetylcholinesterase inhibitors, and the histaminergic agents.

Managing adverse effects

Substance abuse Stimulant abuse has been a concern, but it has not become the problem many feared. In fact, some studies have found that methylphenidate may help stanch the craving for cocaine in adults with ADHD.11,12 Treating ADHD with pharmacotherapy also has been shown to reduce the risk for substance abuse in adolescence by 85%.13

With careful screening, you can usually identify drug-seeking behavior in adult patients. For patients with substance abuse problems, you can prescribe the nonstimulants.

Tics that can occur with stimulant medications usually can be suppressed by reducing the dosage, being vigilant, and waiting it out. Tics may ameliorate over weeks to months.

Cardiac and cognitive effects Long-term use of stimulant medications at high dosages has been associated with cardiac and cognitive toxicity, as noted in the 1998 NIH consensus statement on diagnosis and treatment of ADHD. It is important to provide patients with this information as part of their informed-consent briefing. (See “Related resources,” to view the consensus statement.)

Nonpharmacologic management

Nonpharmacologic treatments such as EEG biofeedback; psychoeducational approaches; and individual, family, and group psychotherapy are widely used to treat adults with ADHD. Clinicians and patients often perceive these interventions as beneficial, although none have been tested in randomized, placebo-controlled studies.

 

 

Patients often function better when their home and work environments are thoughtfully organized, with a designated work/study space and regularly scheduled times for meals, sleep, and exercise. An ADHD coach may facilitate such structure and discipline (Box 2).

New agents in the pipeline

Efforts are being made to increase awareness of adult ADHD and to improve its treatment. For example, the National Institute of Mental Health is funding research on adult ADHD and displays on its Web site a PET scan of an adult brain with ADHD (see “Related resources”).14 Several medications also are being developed to treat ADHD.

Atomoxetine, a nonstimulant medication awaiting FDA approval for adult ADHD, is a selective norepinephrine reuptake inhibitor. In a double-blind, placebo-controlled, crossover study of adults with well-characterized ADHD, 11 of 21 patients improved with use of atomoxetine, compared with 2 of 21 who improved with use of a placebo. The average dosage of 76 mg/d was well-tolerated.15 The 52% response rate is similar to the 54% average improvement rate reported for methylphenidate in previous studies of adult ADHD.

In clinical trials, atomoxetine was given bid. Insomnia was not a side effect, so bid dosing does not interfere with sleep. Approximately 10 to 15% of patients experienced weight loss as a side effect.

Other treatment options under development include:

  • a transdermal system for delivery of methylphenidate16
  • a novel nicotinic analogue
  • glutamate AMPA receptor modulation
  • omega-3 fatty acids.

Related resources

  • Hallowell EM, Ratey JJ. Driven to distraction: Recognizing and coping with attention deficit disorder from childhood through adulthood. New York: Simon and Schuster; Reprint edition 1995.
  • Solanto MV, Arnstein AFT, Castellanos FX, eds. Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press; 2001.
  • Weiss M, Trokenberg-Hechtman L, Weiss G. ADHD in adulthood: A guide to current theory, diagnosis, and treatment. Baltimore: Johns Hopkins University Press; 1999.
  • National Institute of Mental Health. http://www.nimh.nih.gov

Drug brand names

  • Atomoxetine • (investigational)
  • Bupropion • Wellbutrin
  • Desipramine • Norpramin
  • Dextroamphetamine • Dexedrine, Dextrostat
  • Methamphetamine • Desoxyn
  • Methylphenidate • Focalin, Ritalin
  • Methylphenidate SR • Concerta, Metadate CD, Metadate ER, Methylin ER, Ritalin SR
  • Mixed salts of amphetamine • Adderall, Adderall XR
  • Modafinil • Provigil
  • Pemoline • Cylert
  • Venlafaxine • Effexor

Disclosure

The author reports that he serves as a consultant to Eli Lilly and Company and is on the speaker’s bureaus of Wyeth Pharmaceuticals and AstraZeneca.

Attention-deficit/hyperactivity disorder (ADHD) may be the only mental disorder that was discovered in children and later acknowledged in adults. Although controlled studies of adults with ADHD are few, we know that ADHD is common in adults, it can be diagnosed reliably, and 75% of those treated respond to treatment.1

The hallmark symptom of ADHD in children—hyperactivity—is usually attenuated in adults. In fact, some adults prefer the term ADD to ADHD because they are not hyperactive. This may be especially true of women, as their attention problems during childhood often were not recognized as ADHD (Box 1).

Box 1

WHY ADHD IS OFTEN MISSED IN GIRLS

In childhood, girls with ADHD typically present with attention problems and over-talkativeness, rather than hyperactivity. Talking too much does not disrupt the classroom as much as the larger-scale misbehavior of boys with ADHD, so the diagnosis is often missed in these girls. Overtalkativeness was added to the DSM-III-R criteria for ADHD in 1987, after it was recognized as a symptom of overactivity.

Now in midlife, many women with undiagnosed ADHD have children with ADHD. As they bring their children to treatment, these women are recognizing similar attention deficit symptoms from their own childhoods and are getting the help they need. As adults, many have low self-esteem, low energy, and weight problems. Among adults with ADHD, these women may be the most underdiagnosed.

Characteristics of adult ADHD

Adults with ADHD visit a psychiatrist for a variety of reasons. Often they are parents of children diagnosed with ADHD, and the possibility that they are similarly affected has arisen during their children’s evaluation and treatment. Sometimes they have recognized themselves in consumer articles about ADHD, or others have seen them in this light.

Adults with ADHD continue to experience their childhood difficulties in sustaining attention, listening, following instructions, and organizing tasks; inattention to details; lack of sustained mental effort; losing things; distractibility, and forgetfulness. Typical complaints include underachievement and poor adjustment at work or home. Comorbid ADHD may also be identified in patients who present with depression, anxiety, substance misuse, and mood swings.

The cognitive impairment of ADHD continues into adulthood, even in adults without hyperactive symptoms. It may be that adults are not hyperactive because the basal ganglia, which control motor activity in the brain, have over the years accommodated the problem through behavior modification or neurodevelopmental changes in late adolescence.2

Children with ADHD have abnormal cerebrospinal fluid (CSF) and blood levels of the dopaminergic metabolite homovanillic acid (HVA), but adults with ADHD may not. The primary origin for CSF HVA is the nigrostriatum, which suggests that subcortical dopaminergic nuclei are more often affected in children than adults.2 This may mean that compensatory changes occur as persons with ADHD mature, or perhaps the forms of ADHD that persist into adulthood have a different pathology or pathophysiology.

Comorbidities with ADHD

Rarely does one see pure ADHD; comorbidity is the rule. ADHD can be diagnosed quickly if you know what to look for. But a facile diagnosis may overlook a comorbidity that must be treated first—especially if you plan to use stimulants. Many patients with ADHD also have bipolar disorder, and a smaller proportion of patients with bipolar disorder have undetected ADHD. Placing a patient with undetected bipolar disorder on a stimulant could precipitate mania.

Table 1

COMMON COMORBIDITIES WITH ADHD

Bipolar disorder
Anxiety disorder
Depression
Drug dependence
Personality disorders
Somatoform disorders
Tourette’s disorder
Obsessive-compulsive disorder
Intermittent explosive disorder
Impulse control problems
 Addictive behaviors
 Sexual problems
 Compulsive gambling
Learning disabilities
Asperger’s syndrome

From the initial assessment, your treatment plan must address comorbid conditions (Table 1). This means taking a good history that includes corroborating information from relatives and data from the past, if possible. The case will then be much easier to manage, and quality of care greatly enhanced.

Stimulants: Usual first-choice therapy

In most cases, adult ADHD responds well to stimulant medications, although most available evidence is limited to studies in children. Several nonstimulant medications are also available, and the FDA is considering a new-drug application for a medication indicated for adult ADHD. Stimulants produce significant improvement in 30% of patients and mixed results in another 40%. Comorbidities may account for the 10 to 30% of patients who do not respond to stimulant therapy.

Methylphenidate, taken multiple times daily, is the most common treatment for ADHD. Dextroamphetamine and mixed salts of amphetamine also are used (Table 2).3 Patients usually respond to either methylphenidate or an amphetamine, and typically 25% of those who do not respond to one will respond to the other. When the clinical efficacy of amphetamines diminishes over time, many psychiatrists rotate medications. Replacing one amphetamine with another often eliminates the need to slowly increase the dosage and allows the clinician to maintain a relatively stable regimen.

 

 

When administering stimulants to adults, consider the individual’s total dosage requirement and daily schedule. Will he or she fare better with multiple daily dosing or a sustained-release form? How long is his or her average day? Does the patient have to be alert for 12 hours—or longer?

Some patients cannot sleep unless they take their last stimulant dose at bedtime. Others will have insomnia if a last dose is taken too late in the afternoon, especially with a sustained-release formulation.

When starting a patient on stimulants, begin with a 12-hour day and titrate the dosage—usually up, sometimes down—depending on response and side effects. Educating patients about their medications enables them to participate in decision-making.

Common side effects of stimulants include insomnia, decreased appetite, upset stomach, headache, anxiety, agitation, and increased pulse rate and blood pressure. The increase in blood pressure is usually less than 10%, but patients with poorly controlled hypertension should not be treated with stimulants until their blood pressure is well controlled. Until more is known about long-term effects, periodic assessment of blood pressure may be warranted.

Table 2

STIMULANT THERAPY FOR ADULTS WITH ADHD

StimulantsStarting dosageTitration rateUsual dosing intervalMaximum dosage in adults
Methylphenidate
Short-acting
d, l-methylphenidate (Ritalin, Methylin)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 3 to 4 hours Usually bid-tidAverage oral dosage 0.92 mg/kg/d; best response to 1.0 mg/kg/d16
Intermediate-acting
d, l-methylphenidate (Ritalin SR, Metadate ER, Methylin ER)20 mg Ritalin SR; 10 mg Methylin ER or Metadate ER10 to 20 mg per weekqd to bid 
d-methylphenidate (Focalin)2.5 mg bid2.5 to 5 mg per weekbid, at least 4 hours apart 
Long-acting
d, l-methylphenidate (Concerta)18 mg qd18 mg every 3 to 5 days12+ hours, usually qd 
d, l-methylphenidate (Metadate CD)20 mg qd20 mg per weekqd 
Amphetamine
Short-acting
(Dexedrine, Dextrostat)2.5 to 5 mg qd2.5 to 5 mg every 3 to 5 daysEvery 4 to 6 hours Usually bid-tid 
Intermediate-acting
Mixed salts (Adderall)5 mg qd or 5 mg bid5 to 10 mg every 3 to 5 daysEvery 4 to 6 hours Usually qd to bidAverage dosage 54 mg/d divided in two doses; maximum 30 mg bid
(Dexedrine Spansule)5 or 10 mg qd5 mg per weekqd 
Long-acting
(Adderall XR)10 mg qd10 mg per weekqd 
Stimulant
Pemoline (Cylert)37.5 mg qd18.75 mg per weekqd; typical range 56.25 to 75 mg qdMaximum dosage 112.5 mg/d

Box 2

NONDRUG THERAPIES FOR ADULTS WITH ADHD

  • Organized and orderly home and working environment
  • Designated work/study space at home
  • Designated coach to supervise work/study
  • Healthy meals at regularly scheduled times
  • Regular exercise

Adults with ADHD have been treated with mixed amphetamine salts with positive results. In a 7-week controlled, crossover study, 27 adults with ADHD received an average of 54 mg/d administered in two doses. Symptoms improved significantly—a 42% decrease on the ADHD Rating Scale. The medication was well-tolerated, and 70% of those receiving mixed amphetamine salts improved, compared with 7% of those who received a placebo.4

Duration of action of mixed salts of amphetamine has been measured at 3.5 hours with a 5-mg dose and 6.4 hours with a 20-mg dose.5 With methylphenidate, a dose of 12.5 mg worked for 4 hours. The maximum recommended dosage of mixed salts of amphetamine is 40 mg/d in divided doses.

Stimulant medications are well-tolerated. Addiction and the need for increased dosages can occur over long-term use (months to years). Reducing the dosage or switching from methylphenidate to an amphetamine variant can usually prevent these problems.

The FDA recently approved a single-enantiomer form of methylphenidate. It contains only the active “d” enantiomer, whereas the racemic mixture contains both the “d” and “l” enantiomers. Because the “l” enantiomer is inert, the resulting medication is more potent and may be prescribed at half the dosage of the racemic mixture.

Pemoline, a once-daily stimulant, is considered a second-line treatment because of reports of hepatic failure in some patients. Its use requires written informed consent and liver function tests at baseline and every 2 weeks. In a controlled trial, pemoline at high dosages (120 to 160 mg/d) was found moderately effective in adults with ADHD.6

Newer options: Longer-acting stimulants

Newer forms of slow-release methylphenidate and mixed amphetamine salts with sophisticated delivery systems are available.

Metadate CD is delivered in capsules containing beads with polymer coatings that dissolve and release their contents at different times. The capsules contain a 30:70 ratio of immediate- and extended-release beads.

Metadate CD has not been tested for adults in controlled clinical trials. In children ages 6 to 15, a single morning dose has been shown to be clinically effective in the morning and afternoon. A supplemental immediate-release capsule can be given in the morning if a patient’s medication levels need to be increased quickly. Dosage supplementation may also be required later in the day.

 

 

Concerta is delivered in 18-mg and 36-mg tablets. The immediate-release coating on the tablets delivers medication within the first hour. The drug inside then dissolves in the GI tract and is released at a controlled rate by osmotic pressure. The indigestible tablet is passed in the stool.

Concerta was investigated in children ages 6 to 12 and provides 10 to 12 hours of sustained medication. From child studies, we know that when a patient takes a 36-mg tablet at 6 AM, blood levels decline in late afternoon. An 18-mg dose at noon covers the 4 to 6 hours needed for evening chores.

Adderall XR is an extended-release, once-daily form of mixed amphetamine salts. No controlled trials of this formulation are available in adults with ADHD. Its efficacy was established after two clinical trials of children aged 6 to 12 who met DSM-IV criteria for ADHD.

Individualized and flexible dosing improves symptom control and compliance when treating adults with ADHD. For some patients, once-daily dosing is more convenient than multiple doses, while others prefer the immediate-release form because they like its midday “pause” and bid dosing. The immediate-release tablet allows the flexibility of bid or tid dosing, depending on the day’s requirements.

Antidepressants: Another choice

Antidepressants are usually considered second-line treatment for ADHD because of concerns about efficacy and side effects. The few available studies show antidepressants work as well as stimulants but more slowly. It is good practice, therefore, to advise patients that—unlike feeling the effect of a stimulant in 60 minutes—they will not feel an effect from an antidepressant for days or weeks, and that achieving an optimal effect may take 4 to 6 weeks.

Antidepressants have several advantages over stimulants. They are not classified as narcotics, work without the on-off effects of stimulants, and can treat comorbid depression and anxiety. For adult ADHD, the most effective agents work on the catecholamine systems—norepinephrine and/or dopamine. This includes the tricyclic antidepressants, MAO inhibitors, bupropion, and venlafaxine. The serotonin reuptake inhibitors have not shown promise in ADHD, nor have mirtazapine or nefazodone demonstrated much effect.

Desipramine, a tricyclic antidepressant, is a strong inhibitor of norepinephrine reuptake. In a double-blind, controlled study in 41 adults with ADHD, 68% of patients receiving desipramine, 200 mg/d, responded positively, compared with no patients who took a placebo.7

When venlafaxine was given in standard dosages to 10 adults with ADHD in an open, 8-week clinical trial, an effect was seen by week two. Of the nine patients who completed the study, seven were considered responders. Symptoms were reduced significantly with venlafaxine treatment, and most side effects were mild.8

In an open study, bupropion treatment resulted in moderate to marked response in 74% of 19 patients. Ten of those patients who responded chose to continue bupropion rather than their previous medication.9 In a 6-week controlled study of 40 patients, bupropion use was associated with a 42% reduction in ADHD symptoms in the 38 patients who completed the study. Patients who received a placebo showed only a 24% reduction in symptoms. According to the CGI, 52% of patients who received bupropion reported being “much improved” or “very improved” compared with 11% of those receiving a placebo.10

Other treatment options that have shown mixed results include modafinil, alpha-2a agonists, acetylcholinesterase inhibitors, and the histaminergic agents.

Managing adverse effects

Substance abuse Stimulant abuse has been a concern, but it has not become the problem many feared. In fact, some studies have found that methylphenidate may help stanch the craving for cocaine in adults with ADHD.11,12 Treating ADHD with pharmacotherapy also has been shown to reduce the risk for substance abuse in adolescence by 85%.13

With careful screening, you can usually identify drug-seeking behavior in adult patients. For patients with substance abuse problems, you can prescribe the nonstimulants.

Tics that can occur with stimulant medications usually can be suppressed by reducing the dosage, being vigilant, and waiting it out. Tics may ameliorate over weeks to months.

Cardiac and cognitive effects Long-term use of stimulant medications at high dosages has been associated with cardiac and cognitive toxicity, as noted in the 1998 NIH consensus statement on diagnosis and treatment of ADHD. It is important to provide patients with this information as part of their informed-consent briefing. (See “Related resources,” to view the consensus statement.)

Nonpharmacologic management

Nonpharmacologic treatments such as EEG biofeedback; psychoeducational approaches; and individual, family, and group psychotherapy are widely used to treat adults with ADHD. Clinicians and patients often perceive these interventions as beneficial, although none have been tested in randomized, placebo-controlled studies.

 

 

Patients often function better when their home and work environments are thoughtfully organized, with a designated work/study space and regularly scheduled times for meals, sleep, and exercise. An ADHD coach may facilitate such structure and discipline (Box 2).

New agents in the pipeline

Efforts are being made to increase awareness of adult ADHD and to improve its treatment. For example, the National Institute of Mental Health is funding research on adult ADHD and displays on its Web site a PET scan of an adult brain with ADHD (see “Related resources”).14 Several medications also are being developed to treat ADHD.

Atomoxetine, a nonstimulant medication awaiting FDA approval for adult ADHD, is a selective norepinephrine reuptake inhibitor. In a double-blind, placebo-controlled, crossover study of adults with well-characterized ADHD, 11 of 21 patients improved with use of atomoxetine, compared with 2 of 21 who improved with use of a placebo. The average dosage of 76 mg/d was well-tolerated.15 The 52% response rate is similar to the 54% average improvement rate reported for methylphenidate in previous studies of adult ADHD.

In clinical trials, atomoxetine was given bid. Insomnia was not a side effect, so bid dosing does not interfere with sleep. Approximately 10 to 15% of patients experienced weight loss as a side effect.

Other treatment options under development include:

  • a transdermal system for delivery of methylphenidate16
  • a novel nicotinic analogue
  • glutamate AMPA receptor modulation
  • omega-3 fatty acids.

Related resources

  • Hallowell EM, Ratey JJ. Driven to distraction: Recognizing and coping with attention deficit disorder from childhood through adulthood. New York: Simon and Schuster; Reprint edition 1995.
  • Solanto MV, Arnstein AFT, Castellanos FX, eds. Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press; 2001.
  • Weiss M, Trokenberg-Hechtman L, Weiss G. ADHD in adulthood: A guide to current theory, diagnosis, and treatment. Baltimore: Johns Hopkins University Press; 1999.
  • National Institute of Mental Health. http://www.nimh.nih.gov

Drug brand names

  • Atomoxetine • (investigational)
  • Bupropion • Wellbutrin
  • Desipramine • Norpramin
  • Dextroamphetamine • Dexedrine, Dextrostat
  • Methamphetamine • Desoxyn
  • Methylphenidate • Focalin, Ritalin
  • Methylphenidate SR • Concerta, Metadate CD, Metadate ER, Methylin ER, Ritalin SR
  • Mixed salts of amphetamine • Adderall, Adderall XR
  • Modafinil • Provigil
  • Pemoline • Cylert
  • Venlafaxine • Effexor

Disclosure

The author reports that he serves as a consultant to Eli Lilly and Company and is on the speaker’s bureaus of Wyeth Pharmaceuticals and AstraZeneca.

References

1. Gadrow KD, Weiss M. Attention-deficit/hyperactivity disorder in adults: beyond controversy. Arch Gen Psychiatry 2001;58(8):784-5.

2. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998;18(15):5901-7.

3. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43.

4. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58(8):775-82.

5. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34(1):55-60.

6. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19(3):257-64.

7. Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995;183(1):48-50.

8. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57(5):184-9.

9. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147(8):1018-20.

10. Wilens TE, Spencer TJ, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158(2):282-8.

11. Grabowski J, Roache JD, Schmitz JM, Rhoades H, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17(6):485-8.

12. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59(6):300-5.

13. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104(2):e20.-

14. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 1990;323(20):1361-6.

15. Spencer T, Biederman J, Wilens T. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155(5):693-5.

16. Noven Pharmaceuticals. The Science of Noven. Research and development. Transdermal technology. Available at: http://www.noven.com/research.htm.

References

1. Gadrow KD, Weiss M. Attention-deficit/hyperactivity disorder in adults: beyond controversy. Arch Gen Psychiatry 2001;58(8):784-5.

2. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998;18(15):5901-7.

3. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43.

4. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58(8):775-82.

5. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34(1):55-60.

6. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19(3):257-64.

7. Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995;183(1):48-50.

8. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57(5):184-9.

9. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147(8):1018-20.

10. Wilens TE, Spencer TJ, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158(2):282-8.

11. Grabowski J, Roache JD, Schmitz JM, Rhoades H, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17(6):485-8.

12. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59(6):300-5.

13. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104(2):e20.-

14. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 1990;323(20):1361-6.

15. Spencer T, Biederman J, Wilens T. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155(5):693-5.

16. Noven Pharmaceuticals. The Science of Noven. Research and development. Transdermal technology. Available at: http://www.noven.com/research.htm.

Issue
Current Psychiatry - 01(10)
Issue
Current Psychiatry - 01(10)
Page Number
34-43
Page Number
34-43
Publications
Publications
Topics
Article Type
Display Headline
Adult ADHD: Less hyperactivity, but lingering inattention and distress
Display Headline
Adult ADHD: Less hyperactivity, but lingering inattention and distress
Sections
Article Source

PURLs Copyright

Inside the Article